<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Calcium channel blockers for inhibiting preterm labour and birth - Flenady, V - 2014 | Cochrane Library</title> <meta content="Calcium channel blockers for inhibiting preterm labour and birth - Flenady, V - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002255.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Calcium channel blockers for inhibiting preterm labour and birth - Flenady, V - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002255.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002255.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Calcium channel blockers for inhibiting preterm labour and birth" name="citation_title"/> <meta content="Vicki Flenady" name="citation_author"/> <meta content="Mater Research Institute ‐ The University of Queensland (MRI‐UQ)" name="citation_author_institution"/> <meta content="vflenady@mmri.mater.org.au" name="citation_author_email"/> <meta content="Aleena M Wojcieszek" name="citation_author"/> <meta content="Mater Research Institute ‐ The University of Queensland (MRI‐UQ)" name="citation_author_institution"/> <meta content="Dimitri NM Papatsonis" name="citation_author"/> <meta content="Amphia Hospital Breda" name="citation_author_institution"/> <meta content="Owen M Stock" name="citation_author"/> <meta content="Mater Mothers' Hospital, Mater Health Services" name="citation_author_institution"/> <meta content="Linda Murray" name="citation_author"/> <meta content="University of Tasmania" name="citation_author_institution"/> <meta content="Luke A Jardine" name="citation_author"/> <meta content="Mater Mothers' Hospital, Mater Medical Research Institute, The University of Queensland" name="citation_author_institution"/> <meta content="Bruno Carbonne" name="citation_author"/> <meta content="Hopital Trousseau" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD002255.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002255.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002255.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002255.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐Agonists [therapeutic use]; Calcium Channel Blockers [*therapeutic use]; Nifedipine [therapeutic use]; Obstetric Labor, Premature [*prevention &amp; control]; Premature Birth [prevention &amp; control]; Randomized Controlled Trials as Topic; Tocolytic Agents [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002255.pub2&amp;doi=10.1002/14651858.CD002255.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002255\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002255\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002255.pub2",title:"Calcium channel blockers for inhibiting preterm labour and birth",firstPublishedDate:"Jun 5, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002255.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002255.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002255.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002255.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002255.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002255.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002255.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002255.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002255.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002255.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7659 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002255.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-sec-0073"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/table_n/CD002255StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/table_n/CD002255StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Calcium channel blockers for inhibiting preterm labour and birth</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#CD002255-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Vicki Flenady</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#CD002255-cr-0003">Aleena M Wojcieszek</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#CD002255-cr-0004">Dimitri NM Papatsonis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#CD002255-cr-0005">Owen M Stock</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#CD002255-cr-0006">Linda Murray</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#CD002255-cr-0007">Luke A Jardine</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information#CD002255-cr-0008">Bruno Carbonne</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information/en#CD002255-sec-0125">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002255.pub2">https://doi.org/10.1002/14651858.CD002255.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002255-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002255-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002255-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002255-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002255-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002255-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002255-abs-0001" lang="en"> <section id="CD002255-sec-0001"> <h3 class="title" id="CD002255-sec-0001">Background</h3> <p>Preterm birth is a major contributor to perinatal mortality and morbidity, affecting around 9% of births in high‐income countries and an estimated 13% of births in low‐ and middle‐income countries. Tocolytics are drugs used to suppress uterine contractions for women in preterm labour. The most widely used tocolytic are the betamimetics, however, these are associated with a high frequency of unpleasant and sometimes severe maternal side effects. Calcium channel blockers (CCBs) (such as nifedipine) may have similar tocolytic efficacy with less side effects than betamimetics. Oxytocin receptor antagonists (ORAs) (e.g. atosiban) also have a low side‐effect profile. </p> </section> <section id="CD002255-sec-0002"> <h3 class="title" id="CD002255-sec-0002">Objectives</h3> <p>To assess the effects on maternal, fetal and neonatal outcomes of CCBs, administered as a tocolytic agent, to women in preterm labour. </p> </section> <section id="CD002255-sec-0003"> <h3 class="title" id="CD002255-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (12 November 2013). </p> </section> <section id="CD002255-sec-0004"> <h3 class="title" id="CD002255-sec-0004">Selection criteria</h3> <p>All published and unpublished randomised trials in which CCBs were used for tocolysis for women in labour between 20 and 36 completed weeks' gestation. </p> </section> <section id="CD002255-sec-0005"> <h3 class="title" id="CD002255-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial eligibility, undertook quality assessment and data extraction. Results are presented using risk ratio (RR) for categorical data and mean difference (MD) for data measured on a continuous scale with the 95% confidence interval (CI). The number needed to treat to benefit (NNTB) and the number needed to treat to harm (NNTH) were calculated for categorical outcomes that were statistically significantly different. </p> </section> <section id="CD002255-sec-0006"> <h3 class="title" id="CD002255-sec-0006">Main results</h3> <p>This update includes 26 additional trials involving 2511 women, giving a total of 38 included trials (3550 women). Thirty‐five trials used nifedipine as the CCB and three trials used nicardipine. Blinding of intervention and outcome assessment was undertaken in only one of the trials (a placebo controlled trial). However, objective outcomes defined according to timing of birth and perinatal mortality were considered to have low risk of detection bias. </p> <p>Two small trials comparing CCBs with placebo or no treatment showed a significant reduction in birth less than 48 hours after trial entry (RR 0.30, 95% CI 0.21 to 0.43) and an increase in maternal adverse effects (RR 49.89, 95% CI 3.13 to 795.02, one trial of 89 women). Due to substantial heterogeneity, outcome data for preterm birth (less than 37 weeks) were not combined; one placebo controlled trial showed no difference (RR 0.96, 95% CI 0.89 to 1.03) while the other (non‐placebo controlled trial) reported a reduction (RR 0.44, 95% CI 0.31 to 0.62). No other outcomes were reported. </p> <p>Comparing CCBs (mainly nifedipine) with other tocolytics by type (including betamimetics, glyceryl trinitrate (GTN) patch, non‐steriodal anti inflammatories (NSAID), magnesium sulphate and ORAs), no significant reductions were shown in primary outcome measures of birth within 48 hours of treatment or perinatal mortality. </p> <p>Comparing CCBs with betamimetics, there were fewer maternal adverse effects (average RR 0.36, 95% CI 0.24 to 0.53) and fewer maternal adverse effects requiring discontinuation of therapy (average RR 0.22, 95% CI 0.10 to 0.48). Calcium channel blockers resulted in an increase in the interval between trial entry and birth (average MD 4.38 days, 95% CI 0.25 to 8.52) and gestational age (MD 0.71 weeks, 95% CI 0.34 to 1.09), while decreasing preterm and very preterm birth (RR 0.89, 95% CI 0.80 to 0.98 and RR 0.78, 95% CI 0.66 to 0.93); respiratory distress syndrome (RR 0.64, 95% CI 0.48 to 0.86); necrotising enterocolitis (RR 0.21, 95% CI 0.05 to 0.96); intraventricular haemorrhage (RR 0.53, 95% CI 0.34 to 0.84); neonatal jaundice (RR 0.72, 95% CI 0.57 to 0.92); and admissions to neonatal intensive care unit (NICU) (average RR 0.74, 95% CI 0.63 to 0.87). No difference was shown in one trial of outcomes at nine to twelve years of age. </p> <p>Comparing CCBs with ORA, data from one study (which did blind the intervention) showed an increase in gestational age at birth (MD 1.20 completed weeks, 95% CI 0.25 to 2.15) and reductions in preterm birth (RR 0.64, 95% CI 0.47 to 0.89); admissions to the NICU (RR 0.59, 95% CI 0.41 to 0.85); and duration of stay in the NICU (MD ‐5.40 days,95% CI ‐10.84 to 0.04). Maternal adverse effects were increased in the CCB group (average RR 2.61, 95% CI 1.43 to 4.74). </p> <p>Comparing CCBs with magnesium sulphate, maternal adverse effects were reduced (average RR 0.52, 95% CI 0.40 to 0.68), as was duration of stay in the NICU (days) (MD ‐4.55, 95% CI ‐8.17 to ‐0.92). No differences were shown in the comparisons with GTN patch or NSAID, although numbers were small. </p> <p>No differences in outcomes were shown in trials comparing nicardipine with other tocolytics, although with limited data no strong conclusions can be drawn. No differences were evident in a small trial that compared higher‐ versus lower‐dose nifedipine, though findings tended to favour a high dose on some measures of neonatal morbidity. </p> </section> <section id="CD002255-sec-0007"> <h3 class="title" id="CD002255-sec-0007">Authors' conclusions</h3> <p>Calcium channel blockers (mainly nifedipine) for women in preterm labour have benefits over placebo or no treatment in terms of postponement of birth thus, theoretically, allowing time for administration of antenatal corticosteroids and transfer to higher level care. Calcium channel blockers were shown to have benefits over betamimetics with respect to prolongation of pregnancy, serious neonatal morbidity, and maternal adverse effects. Calcium channel blockers may also have some benefits over ORAs and magnesium sulphate, although ORAs results in fewer maternal adverse effects. However, it must be noted that no difference was shown in perinatal mortality, and data on longer‐term outcomes were limited. Further, the lack of blinding of the intervention diminishes the strength of this body of evidence. Further well‐designed tocolytic trials are required to determine short‐ and longer‐term infant benefit of CCBs over placebo or no treatment and other tocolytics, particularly ORAs. Another important focus for future trials is identifying optimal dosage regimens of different types of CCBs (high versus low, particularly addressing speed of onset of uterine quiescence) and formulation (capsules versus tablets). All future trials on tocolytics for women in preterm labour should employ blinding of the intervention and outcome assessment, include measurement of longer‐term effects into early childhood, and also costs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002255-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002255-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002255-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002255-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002255-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002255-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002255-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002255-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002255-abs-0005" lang="en"> <h3>Calcium channel blockers for inhibiting preterm labour and birth</h3> <p>Preterm birth is when a baby is born between 20 and 36 completed weeks' gestation. These babies are generally more ill and are less likely to survive than babies born at term. Preterm babies are also more likely to have some disability, and the earlier the baby is born the more likely they are to have problems. Even short‐term postponement of preterm birth can improve outcomes for babies, as this gives time for the mother to be given a steroid injection to help develop the baby's lungs develop prior to birth. Short‐term postponement of preterm birth may also give the chance to transfer the mother, if required, to somewhere where there is more expert care for the baby available. Drugs used to try and stop labour are called tocolytics. The most common drugs used are betamimetics, but calcium channel blockers (CCBs) are another option. CCBs are commonly used for reducing high blood pressure, but they can also relax uterine contractions. We looked to see if CCBs were effective in postponing labour and improving outcomes for babies, and also whether CCBs were better than betamimetics and other types of tocolytics used to postpone preterm labour and birth. </p> <p>We found 38 trials involving 3550 women, some comparing CCBs (mainly nifedipine) with no tocolytics and others comparing CCBs with tocolytics. The trials included in this review were considered to be of fair quality. We found that CCBs, specifically nifedipine, is better than no tocolytics for postponing preterm birth for 48 hours, which may help improve outcomes for babies. Compared with betamimetics, CCBs were more effective at postponing birth, had fewer side effects for women, and appeared to improve some important short‐term outcomes for the baby (breathing difficulties, gut infections, and admission to special care units). Calcium channel blockers were better than other types of tocolytics for some outcomes only. Oxytocin receptor antagonists (ORAs) appear to have fewer side effects for women than CCBs, but ORAs are not as good at reducing preterm birth. Another type of CCB, nicardipine, was only used in three trials, but was not more effective than other tocolytics. Longer‐term infant and childhood outcomes were not able to be assessed due to lack of available information. In general, CCBs are more effective than betamimetics, but only sometimes more effective than other types of tocolytics. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002255-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002255-sec-0112"></div> <h3 class="title" id="CD002255-sec-0113">Implications for practice</h3> <section id="CD002255-sec-0113"> <p>CCBs (mainly nifedipine) for women in preterm labour have benefits over placebo or no treatment in terms of postponement of birth thus, theoretically, allowing time for administration of antenatal corticosteroids and transfer to higher level care. CCBs were shown to have benefits over betamimetics with respect to prolongation of pregnancy, serious neonatal morbidity, and maternal adverse effects. CCBs may also have some benefits over ORA and magnesium sulphate, although ORA results in fewer maternal adverse effects. The quality of included studies limits the ability for firm conclusions to be drawn. </p> </section> <h3 class="title" id="CD002255-sec-0114">Implications for research</h3> <section id="CD002255-sec-0114"> <p>Further well‐designed tocolytic trials are required to determine short‐ and longer‐term infant benefit of CCB over placebo or no treatment and other tocolytics, particularly ORA. Another important focus for future trials is identifying optimal dosage regimens of nifedipine (high versus low, particularly addressing speed of onset of uterine quiescence) and formulation (capsules versus tablets). All future trials on tocolytics for women in preterm labour should employ blinding of the intervention and outcome assessment and include measurement of longer‐term effects into early childhood, and also costs. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002255-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002255-sec-0029"></div> <section id="CD002255-sec-0030"> <h3 class="title" id="CD002255-sec-0030">Description of the condition</h3> <p>Preterm birth, defined as birth occurring between 20 and 36 completed weeks of gestation is a major contributor to perinatal mortality and morbidity. The rate of preterm birth is increasing across low‐ and middle‐income countries, affecting 8.6% of births in high‐income countries and between 7.4% to 13.3% in low‐ and middle‐income countries (<a href="./references#CD002255-bbs2-0123" title="Eds. HowsonCP , KinneyMV , LawnJE . Born Too Soon: The Global Action Report on Preterm Birth. Geneva: World Health Organization, 2012. ">WHO 2012</a>). Preterm birth is a leading cause of perinatal morbidity including respiratory distress syndrome (RDS), chronic lung disease, intraventricular haemorrhage (IVH), sepsis, cerebral palsy and other forms of neuro‐developmental impairment (<a href="./references#CD002255-bbs2-0080" title="GladstoneM , NeilsonJP , WhiteS , KafulafulaG , van denBroekN . Post‐neonatal mortality, morbidity, and developmental outcome after ultrasound‐dated preterm birth in rural Malawi: a community‐based cohort study. PLoS Medicine2011;8:e1001121. ">Gladstone 2011</a>), blindness and deafness. The birth of a preterm infant who requires intensive care for survival is a crisis, not only for the infant, but also for the parents (<a href="./references#CD002255-bbs2-0093" title="McCainGC , DeatrickJA . The experience of high‐risk pregnancy. Journal of Obstetric, Gynecologic and Neonatal Nursing1993;23:421‐7. ">McCain 1993</a>). The costs to the parents, community and society as a whole, both economic and emotional, are substantial (<a href="./references#CD002255-bbs2-0105" title="PetrouS , EddamaO , ManghamL . A structured review of the recent literature on the economic consequences of preterm birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2011 May;96(3):F225–32. [DOI: 10.1136/adc.2009.161117; Epub 2010 May 20] ">Petrou 2011</a>). </p> <p>Approximately 65% to 70% are spontaneous preterm births either following spontaneous preterm labour (40% to 45%) or those following preterm rupture of membranes (25% to 30%) (<a href="./references#CD002255-bbs2-0081" title="GoldenbergRL , CulhaneJF , IamsJD , RomeroR . Epidemiology and causes of preterm birth. Lancet2008;371:75‐84. ">Goldenberg 2008</a>). While the cause of spontaneous preterm birth is often unclear, some risk factors have been identified including: maternal age (adolescence and advanced age); history of preterm birth; race; multiple pregnancy, short inter‐pregnancy interval; infections; medical conditions; poor nutrition; psychological factors and genetic predisposition (<a href="./references#CD002255-bbs2-0081" title="GoldenbergRL , CulhaneJF , IamsJD , RomeroR . Epidemiology and causes of preterm birth. Lancet2008;371:75‐84. ">Goldenberg 2008)</a>. </p> <p>Despite improvements in the standards in obstetric and neonatal care over recent years, no progress has been made over the last two decades in reducing the incidence of preterm birth in high‐income countries. In fact, rates of preterm birth are rising, in part due to increasing obstetric intervention (<a href="./references#CD002255-bbs2-0081" title="GoldenbergRL , CulhaneJF , IamsJD , RomeroR . Epidemiology and causes of preterm birth. Lancet2008;371:75‐84. ">Goldenberg 2008</a>; <a href="./references#CD002255-bbs2-0098" title="NormanJE , MorrisC , ChalmersJ . The effect of changing patterns of obstetric care in Scotland (1980–2004) on rates of preterm birth and its neonatal consequences: Perinatal Database Study. PLoS MedicineSeptember 2009;6(9):e1000153. ">Norman 2009</a>). Some benefits have been identified from prolongation of pregnancy, which theoretically allows time for corticosteroids to be administered to the mother to hasten fetal lung maturation (<a href="./references#CD002255-bbs2-0109" title="RobertsD , DalzielS . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>), to effect transfer to a centre with neonatal intensive care facilities (<a href="./references#CD002255-bbs2-0107" title="PowellSL , HoltV L , HickokDE , EasterlingT , ConnellFA . Recent changes in delivery site of low‐birth‐weight infants in Washington: impact on birth weight‐specific mortality. American Journal of Obstetrics and Gynecology1995;173(5):1585‐92. ">Powell 1995</a>) and magnesium sulphate administration to reduce the risk of cerebral palsy (<a href="./references#CD002255-bbs2-0077" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>). For these reasons, short‐term tocolytic therapy is commonly used to inhibit preterm labour and postpone preterm birth. </p> </section> <section id="CD002255-sec-0031"> <h3 class="title" id="CD002255-sec-0031">Description of the intervention</h3> <p>Tocolytic drugs have been used to inhibit preterm labour, in order to allow time for co‐intervention and potentially to defer preterm birth, thus improving neonatal outcomes with advancing gestation. A range of tocolytic agents that have been used to inhibit preterm labour are the topics of Cochrane systematic reviews including: nitric oxide donors (glyceryl trinitrate) (<a href="./references#CD002255-bbs2-0078" title="DuckittK , ThorntonS . Nitric oxide donors for the treatment of preterm labour. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD002860] ">Duckitt 2002</a>), oxytocin receptor antagonists (<a href="./references#CD002255-bbs2-0102" title="PapatsonisD , FlenadyV , ColeS , LileyH . Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD004452.pub2] ">Papatsonis 2005</a>), betamimetics (<a href="./references#CD002255-bbs2-0097" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>), magnesium sulphate (<a href="./references#CD002255-bbs2-0076" title="CrowtherCA , HillerJE , DoyleLW . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD001060] ">Crowther 2002</a>), cyclo‐oxygenase (COX) inhibitors (<a href="./references#CD002255-bbs2-0091" title="KingJF , FlenadyV , ColeS , ThorntonS . Cyclo‐oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database of Systematic Reviews2005, Issue Issue 2. [DOI: 10.1002/14651858.CD001992.pub2] ">King 2005</a>) and progesterone (<a href="./references#CD002255-bbs2-0112" title="SuLL , SamuelM , ChongYS . Progestational agents for treating threatened or established preterm labour. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006770.pub2] ">Su 2010</a>), and their relative effects have been explored in a recent network meta‐analysis (<a href="./references#CD002255-bbs2-0085" title="HaasDM , CaldwellDM , KirkpatrickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012</a>). The betamimetics, arguably the most commonly used tocolytics, (ritodrine, salbutamol and terbutaline) have been shown to be effective in delaying delivery by seven days and longer, although no impact has yet been shown on perinatal mortality (<a href="./references#CD002255-bbs2-0097" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>). Furthermore, betamimetics have a high frequency of unpleasant, sometimes severe maternal side effects including tachycardia, hypotension, tremor and a range of biochemical disturbances, and they have been associated with life‐threatening cardiovascular and respiratory events and deaths. COX inhibitors show promise in earlier gestations but in later gestations there remains a concern regarding premature constriction or closure of the ductus arteriosus (<a href="./references#CD002255-bbs2-0092" title="KorenG , FlorescuA , CosteiAM , BoskovicR , MorettiME . Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta‐analysis. Annals of Pharmacotherapy2006;40(5):824‐9. ">Koren 2006</a>). Calcium channel blockers (CCBs) or calcium antagonists are non‐specific smooth muscle relaxants, predominantly used for the treatment of hypertension in adults and are increasingly used as a tocolytic agent for women in preterm labour. </p> </section> <section id="CD002255-sec-0032"> <h3 class="title" id="CD002255-sec-0032">How the intervention might work</h3> <p>Calcium channel blockers exert their tocolytic effect by preventing the influx of extracellular calcium ions into the myometrial cell. They are entirely non‐specific for uterine as distinct from other smooth muscle cells, but have been demonstrated in vitro to have a potent relaxant effect on human myometrium (<a href="./references#CD002255-bbs2-0110" title="SaadeGR , TaskinO , BelfortMA , ErturanB , MoiseKJJr . In vitro comparison of four tocolytic agents, alone and in combination. Obstetrics and Gynecology1994;84:374‐8. ">Saade 1994</a>). The most widely used and studied CCB is nifedipine, which along with nicardipine, belongs to the dihydropiridine group. Nifedipine was first reported in an observational study in 1980 to be an effective tocolytic agent with minimal side effects (<a href="./references#CD002255-bbs2-0114" title="UlmstenU , AnderssonKE , WingerupL . Treatment of premature labor with the calcium antagonist nifedipine. Archives of Gynecology1980;229:1‐5. ">Ulmsten 1980</a>). Nicardipine can be given orally or by intravenous route, whereas nifedipine can only be administered orally. </p> </section> <section id="CD002255-sec-0033"> <h3 class="title" id="CD002255-sec-0033">Why it is important to do this review</h3> <p>Calcium channel blockers have been proposed as effective agents for inhibiting preterm labour and they have less side effects than betamimetics. Betamimetics have a high frequency of unpleasant, sometimes severe maternal side effects including tachycardia, hypotension, tremor and a range of biochemical disturbances. Furthermore, betamimetic treatment is reported to have been associated with at least 25 maternal deaths, mainly from pulmonary oedema (<a href="./references#CD002255-bbs2-0100" title="PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 2001</a>).There is a need therefore for an effective tocolytic agent with fewer side effects than betamimetics. </p> <p>However, concerns arose from animal studies (<a href="./references#CD002255-bbs2-0086" title="HarakeB , GilbertRD , AshwalS , PowerGG . Nifedipine: effects on fetal and maternal haemodynamics in pregnant sheep. American Journal of Obstetrics and Gynecology1987;157:1003‐8. ">Harake 1987</a>) that the CCB nifedipine may have adverse effects on fetal and placental circulation. Although there have been subsequent studies that failed to confirm this (<a href="./references#CD002255-bbs2-0084" title="GucluS , SaygiliU , DoganE , DemirN , BaschatAA . The short‐term effect of nifedipine tocolysis on placental, fetal cerebral and atrioventricular Doppler waveforms. Ultrasound in Obstetrics and Gynecology2004;24:761‐5. ">Guclu 2004</a>; <a href="./references#CD002255-bbs2-0051" title="MeyerWR , RandallHW , GravesWL . Nifedipine versus ritodrine for suppressing preterm labor. Journal of Reproductive Medicine1990;35:649‐53. ">Meyer 1990</a>), it is necessary to review the evidence for the safety and efficacy of this treatment. There have been some incidental case reports that the use of nifedipine in the treatment of preterm labour was associated with more cardiovascular side effects, such as hypotension (<a href="./references#CD002255-bbs2-0117" title="VanVeenAJ , PelinckMJ , vanPampusMG , ErwichJJ . Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG: an International Journal of Obstetrics and Gynecology2005;112:509‐10. ">van Veen 2005</a>), dyspnoea (<a href="./references#CD002255-bbs2-0116" title="VanGeijnHP , LengletJE , BolteAC . Nifedipine trials: effectiveness and safety aspects. BJOG: an international journal of obstetrics and gynecology2005;112(Suppl):79‐83. ">van Geijn 2005</a>), pulmonary oedema (<a href="./references#CD002255-bbs2-0070" title="AbbasOM , NassarAH , KanjNA , UstaIM . Acute pulmonary edema during tocolytic therapy with nifedipine. American Journal of Obstetrics and Gynecology2006;195:e3‐e4. ">Abbas 2006</a>; <a href="./references#CD002255-bbs2-0115" title="VaastP , Dubreucq‐FossaertS , Houfflin‐DebargeV , Provost‐HelouN , Ducloy‐BouthorsAS , PuechF , et al. Acute pulmonary oedema during nicardipine therapy for premature labour; Report of five cases. European Journal of Obstetrics and Gynecology &amp; Reproductive Biology2004;15‐3(113):98‐9. ">Vaast 2004</a>), maternal hypoxia (<a href="./references#CD002255-bbs2-0089" title="HodgesR , Barkehall ‐ThomasA , TippettC . Maternal hypoxia associated with nifedipine for threatened preterm labour. BJOG: an international journal of obstetrics and gynecology2004;4:380‐1. ">Hodges 2004</a>) and myocardial infarction (<a href="./references#CD002255-bbs2-0099" title="OeiSG . Calcium channel blockers for tocolysis: a review of their role and safety following reports of serious adverse events. European Journal of Obstetrics and Gynecology &amp; Reproductive Biology2006;126:137‐45 . ">Oei 2006</a>; <a href="./references#CD002255-bbs2-0118" title="VerhaertD , VanAR . Acute myocardial infarction during pregnancy. Acta Cardiologica2004;59:331‐9. ">Verhaert 2004</a>). These reported incidents were in women with multiple gestations, premature prolonged rupture of membranes (PPROM), vaginal blood loss, diabetes mellitus, or with a cardiovascular history, or who were treated simultaneously with, or immediately following, betamimetics. </p> <p>Another tocolytic, oxytocin receptor antagonists (ORA) have been developed specifically as a tocolytic agent, with atosiban being the most researched and used ORA. ORA relax the myometrium by preventing a rise in intracellular calcium. Preliminary studies in pregnant and non‐pregnant women have suggested a very low incidence of maternal side effects with ORA (<a href="./references#CD002255-bbs2-0082" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13:143‐6. ">Goodwin 1996</a>; <a href="./references#CD002255-bbs2-0083" title="GoodwinTM , ZograbyanA . Oxytocin receptor antagonists: Update. Clinical Perinatology1998;25(4):859‐71. ">Goodwin 1998</a>), most of which are relatively minor: adverse injection site reaction, nausea, vomiting, headache, chest pain and hypotension (<a href="./references#CD002255-bbs2-0094" title="MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM . Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182:1191‐9. ">Moutquin 2000</a>; <a href="./references#CD002255-bbs2-0113" title="TsatsarisV , CarbonneB , CabrolD . Atosiban for preterm labour. Drugs2004;64:375‐82. ">Tsatsaris 2004</a>). </p> <p>A recent network meta‐analysis of tocolytic agents concluded that prostaglandin inhibitors and CCBs had the highest probability of delaying delivery and improving neonatal and maternal outcomes (<a href="./references#CD002255-bbs2-0085" title="HaasDM , CaldwellDM , KirkpatrickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012</a>). There are however, concerns regarding the potentially deleterious effects of prolonged exposure to COX inhibition on the fetal cardiovasculature, gut and kidney (<a href="./references#CD002255-bbs2-0104" title="PerronN , TremblayE , FerrettiE , BabakissaC , SeidmanEG , LevyE , et al. Deleterious effects of indomethacin in the mid‐gestation human intestine. Genomics2013;101(3):171‐7. ">Perron 2013</a>; <a href="./references#CD002255-bbs2-0122" title="WalkerMW , ClarkRH , SpitzerAR . Elevation in plasma creatinine and renal failure in premature neonates without major anomalies: terminology, occurrence and factors associated with increased risk. Journal of Perinatology2011;31(3):199‐205. ">Walker 2011</a>). In addition, there are concerns regarding the increase in infant mortality with the use of magnesium sulphate for the treatment of preterm birth rightly limit its utility as a first‐line tocolytic (<a href="./references#CD002255-bbs2-0076" title="CrowtherCA , HillerJE , DoyleLW . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD001060] ">Crowther 2002</a>). </p> <p>It is therefore important to undertake a systematic review of all randomised controlled trials of CCBs used in the management of women in preterm labour to determine the relative risks and benefits of this intervention. A series of Cochrane reviews have assessed the effects of different classes of tocolytics compared with placebo, and with each other (<a href="./references#CD002255-bbs2-0074" title="BainE , HeatleyE , HsuK , CrowtherCA . Relaxin for preventing preterm birth. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010073.pub2] ">Bain 2013</a>; <a href="./references#CD002255-bbs2-0076" title="CrowtherCA , HillerJE , DoyleLW . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD001060] ">Crowther 2002</a>; <a href="./references#CD002255-bbs2-0078" title="DuckittK , ThorntonS . Nitric oxide donors for the treatment of preterm labour. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD002860] ">Duckitt 2002</a>; <a href="./references#CD002255-bbs2-0091" title="KingJF , FlenadyV , ColeS , ThorntonS . Cyclo‐oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database of Systematic Reviews2005, Issue Issue 2. [DOI: 10.1002/14651858.CD001992.pub2] ">King 2005</a>; <a href="./references#CD002255-bbs2-0102" title="PapatsonisD , FlenadyV , ColeS , LileyH . Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD004452.pub2] ">Papatsonis 2005</a>; <a href="./references#CD002255-bbs2-0112" title="SuLL , SamuelM , ChongYS . Progestational agents for treating threatened or established preterm labour. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006770.pub2] ">Su 2010</a>; <a href="./references#CD002255-bbs2-0097" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>). A review on combinations of different tocolytics for women in preterm labour is the subject of a review currently in development (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004352.pub3/full#CD004352-bbs2-0112" target="_blank">Nardin 2006</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002255-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002255-sec-0034"></div> <p> <ol id="CD002255-list-0001"> <li> <p>To assess the effects on maternal, fetal, and neonatal outcomes of CCBs administered as a tocolytic agent to women in preterm labour when compared with either placebo or no intervention. </p> </li> <li> <p>To assess the effects on maternal, fetal, and neonatal outcomes of CCBs administered as a tocolytic agent to women in preterm labour when compared with other tocolytic agents. </p> </li> <li> <p>To assess the effects on maternal, fetal, and neonatal outcomes of different types of CCBs. </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002255-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002255-sec-0035"></div> <section id="CD002255-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002255-sec-0037"> <h4 class="title">Types of studies</h4> <p>All published and unpublished randomised and cluster‐randomised trials in which CCBs were used for tocolysis in the management of preterm labour. We excluded trials using quasi‐random methods of allocation and cross‐over trials. </p> </section> <section id="CD002255-sec-0038"> <h4 class="title">Types of participants</h4> <p>Women assessed as being in preterm labour (between 20 and 36 completed weeks' gestation) and considered suitable candidates for tocolysis. </p> </section> <section id="CD002255-sec-0039"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD002255-list-0002"> <li> <p>CCB administered as a tocolytic by any route compared with placebo, no treatment or any other tocolytic. </p> </li> <li> <p>High‐dose nifedipine compared with low‐dose nifedipine.</p> </li> </ol> </p> </section> <section id="CD002255-sec-0040"> <h4 class="title">Types of outcome measures</h4> <p>We aimed to examine the effect of CCBs on clinically important outcome measures related to prolonging the duration of pregnancy, as well as infant morbidity and mortality and maternal side effects. </p> <p>Clinically relevant outcomes for trials of tocolysis for inhibiting preterm labour have been prespecified following consultation with the editors and authors of the individual reviews. </p> <p>Consensus was reached on a set of six ‘core’ outcomes, which are highlighted below. These will be included in all tocolysis reviews. In addition to these core outcomes, individual teams may include other outcomes as necessary. </p> <section id="CD002255-sec-0041"> <h5 class="title">Primary outcomes</h5> <p>Primary outcomes were chosen to be most representative of the clinically important measures of effectiveness and complications. Serious outcomes for the women and their infants are composite endpoints. All these events individually were expected to be rare and a modest change in their incidence more likely to be detected by using composite outcomes. The incidence of individual components was explored in the secondary outcomes. Primary outcomes were: </p> <p> <ol id="CD002255-list-0003"> <li> <p><b>serious maternal outcome</b> (defined as death, cardiac arrest, respiratory arrest, admission to intensive care unit); </p> </li> <li> <p><b>birth less than 48 hours after trial entry</b>; </p> </li> <li> <p><b>serious infant outcome</b> (defined as death or chronic lung disease [need for supplemental oxygen at 28 days of life or later], grade three or four intraventricular haemorrhage (IVH) or periventricular leukomalacia (PVL), major neurosensory disability (defined as any of legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay/intellectual impairment [defined as developmental quotient (DQ) or intelligence quotient (IQ) less than 2 standard deviations below mean]); </p> </li> <li> <p><b>perinatal mortality</b> (stillbirth defined as a birth not showing signs of life defined by any gestational age and birthweight in the trials and neonatal death up to 28 days); </p> </li> <li> <p><b>very preterm birth</b> (before completion of 34 weeks of gestation). </p> </li> </ol> </p> </section> <section id="CD002255-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes include other measures of effectiveness, complications, satisfaction with care and health service use. </p> <p>For the infant/child these were:</p> <p> <ol id="CD002255-list-0004"> <li> <p>gestational age at birth;</p> </li> <li> <p>preterm birth (before completion of 37 weeks of gestation);</p> </li> <li> <p>extremely preterm birth (before completion of 28 weeks of gestation);</p> </li> <li> <p>interval between trial entry and birth;</p> </li> <li> <p>Apgar score less than seven at five minutes;</p> </li> <li> <p>admission to neonatal intensive care (NICU) nursery;</p> </li> <li> <p>respiratory distress syndrome (RDS);</p> </li> <li> <p>chronic lung disease (need for supplemental oxygen at 28 days of life or later);</p> </li> <li> <p>necrotising enterocolitis (NEC);</p> </li> <li> <p>neonatal sepsis;</p> </li> <li> <p>neonatal jaundice;</p> </li> <li> <p>IVH;</p> </li> <li> <p>grade three or four IVH;</p> </li> <li> <p>periventricular leukomalacia (PVL);</p> </li> <li> <p>retinopathy of prematurity (ROP);</p> </li> <li> <p>developmental delay or intellectual impairment;</p> </li> <li> <p>blindness, deafness, cerebral palsy;</p> </li> <li> <p>psychosocial outcome measures; and</p> </li> <li> <p>quality of life.</p> </li> </ol> </p> <p>For the woman these were:</p> <p> <ol id="CD002255-list-0005"> <li> <p>admission to intensive care unit;</p> </li> <li> <p>major adverse effects (respiratory depression, hypotension, tachycardia);</p> </li> <li> <p>minor adverse effects of therapy (including nausea, vomiting);</p> </li> <li> <p>discontinuation of therapy for maternal adverse effects;</p> </li> <li> <p><b>any maternal adverse effects</b>; </p> </li> <li> <p>women's satisfaction with the therapy;</p> </li> <li> <p>bleeding episodes (antepartum haemorrhage (APH), postpartum haemorrhage (PPH), need for transfusion); </p> </li> <li> <p>mode of delivery (caesarean section);</p> </li> <li> <p>parental stress/anxiety; and</p> </li> <li> <p>quality of life.</p> </li> </ol> </p> <p>Health services utilisation was assessed via:</p> <p> <ol id="CD002255-list-0006"> <li> <p>duration of stay in NICU nursery (days);</p> </li> <li> <p>duration of stay in maternal hospital (days); and</p> </li> <li> <p>cost.</p> </li> </ol> </p> <p>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group. </p> </section> </section> </section> <section id="CD002255-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002255-sec-0044"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register by contacting the Trials Search Co‐ordinator (12 November 2013). </p> <p>The Cochrane Pregnancy and Childbirth Group’s Trials Register is maintained by the Trials Search Co‐ordinator and contains trials identified from: </p> <p> <ol id="CD002255-list-0007"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE;</p> </li> <li> <p>weekly searches of Embase;</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the ‘Specialized Register’ section within the editorial information about the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth Group</a>. </p> <p>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co‐ordinator searches the register for each review using the topic list rather than keywords. </p> <p>We did not apply any language restrictions.</p> </section> </section> <section id="CD002255-sec-0045"> <h3 class="title" id="CD002255-sec-0045">Data collection and analysis</h3> <p>For the methods used in the previous version of this review, <i>see</i><a href="./references#CD002255-bbs2-0125" title="KingJF , FlenadyV , PapatsonisD , DekkerG , CarbonneB . Calcium channel blockers for inhibiting preterm labour. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD002255] ">King 2003</a>. </p> <p>For this update, we applied the following methods to all previously included and new studies. </p> <section id="CD002255-sec-0046"> <h4 class="title">Selection of studies</h4> <p>At least two review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third person. </p> </section> <section id="CD002255-sec-0047"> <h4 class="title">Data extraction and management</h4> <p>The review authors used the standard methods of The Cochrane Collaboration and considered all potential trials for inclusion. At least two review authors (V Flenady, A Wojcieszek, L Murray, or O Stock) evaluated the methodological quality and extracted trial data independently, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD002255-bbs2-0088" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We resolved discrepancies through discussion. We entered data into Review Manager software (<a href="./references#CD002255-bbs2-0108" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and checked them for accuracy. </p> <p>When information was unclear, we attempted to contact authors of the original reports to provide further details. </p> </section> <section id="CD002255-sec-0048"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002255-bbs2-0088" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>)<i>.</i> We resolved any disagreement by discussion or by involving a third assessor<i>.</i> </p> <section id="CD002255-sec-0049"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD002255-list-0008"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD002255-sec-0050"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the method as:</p> <p> <ul id="CD002255-list-0009"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.   </p> </li> </ul> </p> </section> <section id="CD002255-sec-0051"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the method as:</p> <p> <ul id="CD002255-list-0010"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD002255-sec-0052"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD002255-list-0011"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> <p>With respect to 3.2, we divided the assessment of outcome measures into two groups (subjective and objective) according to the propensity for bias to result in a deviation from the true effect in the absence of blinding. For these groups we considered the likelihood of bias arising as a result of co‐intervention and/or lack of clearly stated definitions. Subjective outcomes were those considered to have a potentially higher risk of bias as follows: admission to NICU nursery, length of nursery stay, neonatal morbidity (RDS, NEC, IVH, jaundice, ROP), maternal length of hospital stay, maternal adverse effects, and discontinuation of therapy for maternal adverse effects. Objective measures considered to be less likely influenced by detection or performance bias were: stillbirth, neonatal death, perinatal death, birth within 48 hours of trial entry, preterm birth, and gestation at birth. </p> </section> <section id="CD002255-sec-0053"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes.  Where sufficient information was reported, or was supplied by the trial authors, we re‐included missing data in the analyses that we undertook. </p> <p>We assessed the method as:</p> <p> <ul id="CD002255-list-0012"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD002255-sec-0054"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the method as:</p> <p> <ul id="CD002255-list-0013"> <li> <p>low risk of bias (where it is clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD002255-sec-0055"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD002255-list-0014"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD002255-sec-0056"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Handbook</i> (<a href="./references#CD002255-bbs2-0088" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we consider it is likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses ‐ <i>see</i><a href="#CD002255-sec-0072">Sensitivity analysis</a>.<i> </i> </p> </section> </section> <section id="CD002255-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <section id="CD002255-sec-0058"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we present results as summary risk ratios with 95% confidence intervals (CI).<i> </i>Number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH) with 95% confidence interval (CI) presented where appropriate. </p> </section> <section id="CD002255-sec-0059"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference if outcomes are measured in the same way between trials. We planned to use the standardised mean difference to combine trials that measure the same outcome, but used different methods. <b> </b> </p> </section> </section> <section id="CD002255-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <section id="CD002255-sec-0061"> <h5 class="title">Cross‐over trials</h5> <p>We excluded cross‐over trials.</p> </section> <section id="CD002255-sec-0062"> <h5 class="title">Cluster‐randomised trials</h5> <p>We did not identify any cluster‐randomised trials for inclusion in this review, but we may include trials of this type in future updates. </p> <p>If cluster‐randomised trials are included in future reviews, we plan to include cluster‐randomised trials in the analyses along with individually‐randomised trials. Their sample sizes will be adjusted using the methods described in the <i>Handbook</i> (<a href="./references#CD002255-bbs2-0088" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) using an estimate of the intracluster correlation co‐efficient (ICC) derived from the trial (if possible), or from another source. If ICCs from other sources are used, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomised trials and individually‐randomised trials, we plan to synthesise the relevant information. We consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation units. </p> </section> <section id="CD002255-sec-0063"> <h5 class="title">Multiple pregnancy</h5> <p>The analysis in this review involves multiple pregnancies, therefore, wherever possible, analyses should be adjusted for clustering to take into account the non‐independence of babies from the same pregnancy (<a href="./references#CD002255-bbs2-0079" title="GatesS , BrocklehurstP . How should randomised trials including multiple pregnancies be analysed?. BJOG: an international journal of obstetrics and gynecology2004;111(3):213‐29. ">Gates 2004</a>). Treating babies from multiple pregnancies as if they are independent, when they are more likely to have similar outcomes than babies from different pregnancies, will overestimate the sample size and give confidence intervals that are too narrow. Each woman can be considered a cluster in multiple pregnancy, with the number of individuals in the cluster being equal to the number of fetuses in her pregnancy. Analysis using cluster trial methods allows calculation of risk ratio and adjustment of confidence intervals. Usually this will mean that the confidence intervals get wider. Although this may make little difference to the conclusion of a trial, it avoids misleading results in those trials where the difference may be substantial. </p> <p>We planned to adjust for clustering in the analyses, wherever possible, and to use the inverse variance method for adjusted analyses, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002255-bbs2-0088" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and in <a href="./references#CD002255-bbs2-0124" title="YellandLN , SalteraAB , RyanaP , MakridesbM . Analysis of binary outcomes from randomised trials including multiple births: When should clustering be taken into account?. Paediatric and Perinatal Epidemiology2011;25:283–97. ">Yelland 2011</a>. </p> </section> </section> <section id="CD002255-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial is the number randomised minus any participants whose outcomes are known to be missing. </p> </section> <section id="CD002255-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if the I² was greater than 30% and either Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD002255-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>If 10 or more studies had contributed data to meta‐analysis for any particular outcome, we investigated reporting biases (such as publication bias) using funnel plots. We assessed possible asymmetry visually. If asymmetry was suggested by a visual assessment, we planned to perform exploratory analyses to investigate it. </p> </section> <section id="CD002255-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager software (<a href="./references#CD002255-bbs2-0108" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We used fixed‐effect meta‐analysis for combining data where it is reasonable to assume that studies are estimating the same underlying treatment effect: i.e. where trials are examining the same intervention, and the trials’ populations and methods are judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary if an average treatment effect across trials was considered clinically meaningful. </p> <p>The random‐effects summary was treated as the average range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect had not been clinically meaningful, we would not have combined trials. </p> <p>Where random‐effects analyses were used, the results were presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I². </p> </section> <section id="CD002255-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Had we identified substantial heterogeneity, we planned to investigate it using subgroup analyses and consider whether an overall summary was meaningful, and if so, use random‐effects analysis to produce it. We planned to assess subgroup differences by interaction tests available within RevMan (<a href="./references#CD002255-bbs2-0108" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> <p>We were unable to conduct the planned subgroup analyses to explore the effects at different gestational age thresholds by membrane status and multiple gestation due to the unavailability of data. </p> <section id="CD002255-sec-0069"> <h5 class="title">A priori subgroup analyses</h5> <p>Subgroup analyses were as follows.</p> <section id="CD002255-sec-0070"> <h6 class="title">By intervention</h6> <p> <ul id="CD002255-list-0015"> <li> <p>Type of other tocolytic.</p> </li> <li> <p>Type of CCB.</p> </li> </ul> </p> </section> <section id="CD002255-sec-0071"> <h6 class="title">By population</h6> <p> <ul id="CD002255-list-0016"> <li> <p>Women with preterm labour prior to 28 weeks' gestation versus women at 28 weeks or more. </p> </li> <li> <p>Women with ruptured membranes versus women with intact membranes.</p> </li> <li> <p>Women with multiple pregnancy versus women with a singleton pregnancy.</p> </li> </ul> </p> <p>The following outcomes will be used in subgroup analysis in future updates of this review. </p> <p> <ul id="CD002255-list-0017"> <li> <p>Birth less than 48 hours after trial entry.</p> </li> <li> <p>Extremely preterm birth (before completion of 28 weeks of gestation).</p> </li> <li> <p>Very preterm birth (before completion of 34 weeks of gestation).</p> </li> <li> <p>Preterm birth (before completion of 37 weeks of gestation).</p> </li> <li> <p>Perinatal mortality.</p> </li> <li> <p>Respiratory distress syndrome.</p> </li> <li> <p>Serious infant outcome (defined as death or chronic lung disease [need for supplemental oxygen at 28 days of life or later], grade three or four IVH or PVL, major sensorineural disability (defined as any of legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay/intellectual impairment [defined as developmental quotient (DQ) or intelligence quotient (IQ) less than 2 standard deviation below mean])). </p> </li> <li> <p>Serious maternal outcome (defined as death, cardiac arrest, respiratory arrest, admission to intensive care unit). </p> </li> <li> <p>Discontinuation of therapy for maternal adverse effects.</p> </li> </ul> </p> </section> </section> </section> <section id="CD002255-sec-0072"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates (greater than 20%), or both, with poor‐quality studies (including those assessed as low or unknown risk of bias) being excluded from the analyses in order to assess whether this made any difference to the overall result. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002255-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002255-sec-0073"></div> <section id="CD002255-sec-0074"> <h3 class="title">Description of studies</h3> <section id="CD002255-sec-0075"> <h4 class="title">Results of the search</h4> <p>In total, 69 studies were identified as potentially eligible for inclusion in this review. Eighteen studies were excluded (<a href="./references#CD002255-bbs2-0039" title="Al‐OmariWR , Al‐ShammaaHB , Al‐TikritiEM , AhmedKW . Atosiban and nifedipine in acute tocolysis: A comparative study. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;128:129‐34. Al‐OmariWR , Al‐TikritiE , Al‐ShammaH . Atosiban and nifedipine in acute tocolysis, comparative study [abstract]. XVIIIth European Congress of Obstetrics and Gynaecology; 2004 May 12‐15; Athens, Greece. 2004:103. ">Al‐Omari 2006</a>; <a href="./references#CD002255-bbs2-0040" title="BreartG , SureauC , Rumeau‐RouquetteC . A study of the comparative efficiency of ifenprodil and ritodrine in the treatment of threatening premature labour [translation]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1979;8(3):261‐3. ">Breart 1979</a>; <a href="./references#CD002255-bbs2-0041" title="CarrDB , ClarkAL , KernekK , SpinnatoJA . Maintenance oral nifedipine for preterm labor: a randomised clinical trial. American Journal of Obstetrics and Gynecology1999;181(4):822‐7. ">Carr 1993</a>; <a href="./references#CD002255-bbs2-0042" title="ChawanpaiboonS , PimolK , SirisomboonR . Comparison of success rate of nifedipine, progesterone, and bed rest for inhibiting uterine contraction in threatened preterm labor. Journal of Obstetrics and Gynaecology Research2011;37(7):787‐91. ChawanpaiboonS , SutantawibulA , PimolK , SirisomboonR , WorapitaksanondS . Preliminary study: Comparison of the efficacy of progesterone and nifedipine in inhibiting threatened preterm labour in Siriraj Hospital. Thai Journal of Obstetrics and Gynaecology2009;17:23‐9. ">Chawanpaiboon 2011</a>; <a href="./references#CD002255-bbs2-0043" title="DasariP , KodencheryMM . Psychological factors in preterm labor and psychotherapeutic intervention. International Journal of Gynaecology &amp; Obstetrics2007;97(3):196‐7. ">Dasari 2007</a>; <a href="./references#CD002255-bbs2-0044" title="Dunstan‐BooneG , BondA , ThorntonYS . A comparison of verapamil vs ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990; Houston, Texas, USA, 1990:83. 1990:83. ">Dunstan‐Boone 1990</a>; <a href="./references#CD002255-bbs2-0045" title="El‐SayedYY , HolbrookRHJr , GibsonR , ChitkaraU , DruzinML , BabaD . Diltiazem for maintenance tocolysis of preterm labor: comparison to nifedipine in a randomized trial. Journal of Maternal‐Fetal Medicine1998;7(5):217‐21. ">El‐Sayed 1998</a>; <a href="./references#CD002255-bbs2-0046" title="HussleinP , Cabero RouraL , DudenhausenJW , HelmerH , FrydmanR , RizzoN , et al. Atosiban versus usual care for the management of preterm labor. Journal of Perinatal Medicine2007;35(4):305‐13. ">Husslein 2007</a>; <a href="./references#CD002255-bbs2-0047" title="JunejoN , MumtazF , UnarBA . Comparison of salbutamol and nifedipine as a tocolytic agent in the treatment of preterm labor. Journal of Liaquat University of Medical and Health Sciences2008;7(2):115‐9. ">Junejo 2008</a>; <a href="./references#CD002255-bbs2-0048" title="JuonAM , Kühn‐VeltenWN , BurkhardtT , KrahenmannF , ZimmermannR , vonMandachU . Nifedipine gastrointestinal therapeutic system (GITS) as an alternative to slow‐release for tocolysis‐‐tolerance and pharmacokinetic profile. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2008;140:27‐32. ">Juon 2008</a>; <a href="./references#CD002255-bbs2-0049" title="MaitraN , ChristianV , KavishvarA . Tocolytic efficacy of nifedipine versus ritodrine in preterm labor. International Journal of Gynecology &amp; Obstetrics2007;97(2):147‐8. MaitraN , ChristianV , VermaRN , DesaiVA . Maternal and fetal cardiovascular side effects of nifedipine and ritodrine used as tocolytics. Journal of Obstetrics and Gynaecology of India2007;57(2):131‐4. ">Maitra 2007</a>; <a href="./references#CD002255-bbs2-0050" title="MalikKK . Comparison of nifedipine with salbutamol as tocolytic agents in preterm labour. Biomedica2007;23:111‐5. ">Malik 2007</a>; <a href="./references#CD002255-bbs2-0051" title="MeyerWR , RandallHW , GravesWL . Nifedipine versus ritodrine for suppressing preterm labor. Journal of Reproductive Medicine1990;35:649‐53. ">Meyer 1990</a>; <a href="./references#CD002255-bbs2-0052" title="PapadopoulosV , DecavalasG , TzingounisV . Nifedipine versus ritodrine in the treatment of preterm labor. Acta Obstetricia et Gynecologica Scandinavica Supplement1997;76(167:1):88. ">Papadopoulos 1997</a>; <a href="./references#CD002255-bbs2-0053" title="PiovanoA , CarboniF , CasaleO , D'AngeloA , OsesA . Calcium antagonism in the control of adverse reactions during utero‐inhibition. Archives of Gynecology1985;237 Suppl 1:98. ">Piovano 1985</a>; <a href="./references#CD002255-bbs2-0054" title="Rodriguez‐EscuderoFJ , ArangurenG , BenitoJA . Verapamil to inhibit the cardiovascular side effects of ritodrine. International Journal of Gynecology and Obstetrics1981;19:333‐6. ">Rodriguez‐Escudero 1981</a>; <a href="./references#CD002255-bbs2-0055" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG: an International Journal of Obstetrics and Gynaecology2006;113(11):1228‐34. ">Shim 2006</a>; <a href="./references#CD002255-bbs2-0056" title="SmithCS , WoodlandMB . Clinical comparison of oral nifedipine and subcutaneous terbutaline for initial tocolysis. American Journal of Perinatology1993;10:280‐4. WoodlandMB , SmithC , ByersJ , BologneseR , WeinerS . Clinical comparison of oral nifedipine and subcutaneous terbutaline use for initial tocolysis. Proceedings of 10th Annual meeting of Society of Perinatal Obstetricans; 1990; Houston, Texas, USA. 1990:523. ">Smith 1993</a>). </p> <p>An additional nine studies are awaiting classification awaiting further information from the authors (<a href="./references#CD002255-bbs2-0057" title="YiCS , KimDK . A comparison of tocolytic effects of ritodrine hydrochloride and nifedipine in the treatment of preterm labour. Journal of Catholic Medical College1991;44(1):231‐8. ">Chong 1991</a>; <a href="./references#CD002255-bbs2-0058" title="deHeusR , MulderEJ , DerksJB , VisserGH . The effects of the tocolytics atosiban and nifedipine on fetal movements, heart rate and blood flow. Journal of Maternal‐Fetal &amp; Neonatal Medicine2009;22(6):485‐90. ">de Heus 2009</a>; <a href="./references#CD002255-bbs2-0059" title="DubayP , SinghalD , BhagoliwalA , MishraRS . Assessment of newborns of mothers treated with nifedipine and isoxsuprine. Journal of Obstetrics and Gynecology of India1992;42(6):778‐80. ">Dubay 1992</a>; <a href="./references#CD002255-bbs2-0060" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD002255-bbs2-0061" title="LotfalizadehM , TeymooriM . Comparison of nifedipine and magnesium sulfate in the treatment of preterm. Iranian Journal of Obstetrics, Gynecology and Infertility2010; Vol. 13, issue 2. ">Lotfalizadeh 2010</a>; <a href="./references#CD002255-bbs2-0062" title="MathewS , Ashok . A comparative study of tocolytic effect of nifedipine and isoxsuprine hydrochloride. Acta Obstetricia et Gynecologica Scandinavica1997;76(167):90. ">Mathew 1997</a>; <a href="./references#CD002255-bbs2-0063" title="RoyUK , PanS . Use of calcium antagonist (nifedipine) in premature labour. Journal of the Indian Medical Association1993;91(1):8‐10. ">Roy 1993</a>; <a href="./references#CD002255-bbs2-0064" title="SharmaA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labour [abstract]. XVI FIGO World Congress of Obstetrics &amp; Gynecology; 2000 Sept 3‐8; Washington DC, USA. 2000:Book 2; 156. ">Sharma 2000</a>; <a href="./references#CD002255-bbs2-0065" title="SofatR , GillBK , GoyalA . Comparison of nifedipine and isoxsuprine in the arrest of preterm labour. International Journal of Gynecology and Obstetrics1994;46 Suppl:59. ">Sofat 1994</a>). For further information, please see <a href="./references#CD002255-sec-0133" title="">Characteristics of studies awaiting classification</a>. </p> <p>Four ongoing were identified as follows: nifedipine versus atosiban (<a href="./references#CD002255-bbs2-0066" title="OudijkMA , HeidaKY , MolBW , vanVlietEOG . Assessment of perinatal outcome by use of specific tocolytics in early labour. Subtitle: Nifedipine versus Atosiban in the treatment of threatened preterm labour. http://www.studies‐obsgyn.nl/apostel3/page.asp?page_id=931(accessed 18 November 2013). ">APOSTEL III 2011</a>; <a href="./references#CD002255-bbs2-0067" title="Gonzalez GonzalezL . Administration of Nifidepine versus Atosiban in pregnant women with a threat of premature labor. ClinicalTrials.gov (accessed 21 May 2013)2011. ">Gonzalez 2011</a>); nifedipine versus magnesium sulphate (<a href="./references#CD002255-bbs2-0068" title="SnyderS . Trial to compare the efficacy of nifedipine and magnesium sulfate as tocolytics. Personal Communication1989. ">Snyder 1989</a>); nifedipine versus placebo (<a href="./references#CD002255-bbs2-0069" title="VisJ , OpmeerB , van derPostJ , vanStraalenJ , MolBW , KokJ , et al. Does fibronectin status influence the effectiveness of sustained tocolysis in women with threatened preterm labor?. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S199. VisJY , WilmsFF , OudijkMA , PorathMM , ScheepersHC , BloemenkampKW , et al. Cost‐effectiveness of fibronectin testing in a triage in women with threatened preterm labor: alleviation of pregnancy outcome by suspending tocolysis in early labor (APOSTEL‐I trial). BMC Pregnancy and Childbirth2009;9:38. ">Vis 2009</a>). For further information, please see <a href="./references#CD002255-sec-0134" title="">Characteristics of ongoing studies</a>. </p> <p>An additional 26 trials involving 2511 women have been included in this update, giving a total of 38 included trials (involving 3550 women) testing the effects of CCB for tocolysis in preterm labour; the previous version included 12 trials and 1039 women. </p> </section> <section id="CD002255-sec-0076"> <h4 class="title">Included studies</h4> <p>Two included studies (173 women) compared CCB with placebo or no treatment (<a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a>; <a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a>). Thirty‐five included trials (3275 women) compared CCB with other tocolytic agents for preterm labour (<a href="./references#CD002255-bbs2-0001" title="Al‐QattanF , OmuAE , LabeebN . A prospective randomized study comparing nifedipine versus ritodrine for the suppression of preterm labour. Medical Principles &amp; Practice2000;9:164‐73. ">Al‐Qattan 2000</a>; <a href="./references#CD002255-bbs2-0002" title="AmorimMM , LippoLA , CostaAA , CoutinhoIC , SouzaAS . Transdermal nitroglycerin versus oral nifedipine administration for tocolysis: a randomized clinical trial [Nitroglicerina transdermica versus nifedipina oral para inibicao do trabalho de parto prematuro: ensaio clinico randomizado]. Revista Brasileira de Ginecologia e Obstetricia2009;31(11):552‐8. ">Amorim 2009</a>; <a href="./references#CD002255-bbs2-0004" title="BraceroLA , LeikenE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:77. BraceroLA , LeikinE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. American Journal of Perinatology1991;8(6):365‐9. ">Bracero 1991</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0006" title="FanL , WuGF , HuangXH . The effect of calcium entry on the management of preterm labor ‐ a randomized controlled study. Chinese Journal of Practical Gynecology and Obstetrics2003;19(2):87‐9. ">Fan 2003</a>; <a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a>; <a href="./references#CD002255-bbs2-0010" title="Garcia‐VelascoJA , Gonzalez GonzalezA . A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. International Journal of Gynaecology and Obstetrics1998;61:239‐44. ">Garcia‐Velasco 1998</a>; <a href="./references#CD002255-bbs2-0011" title="GeorgeSS , GeorgeK , JairajP . A randomized controlled study of nifedipine and isoxuprine in the treatment of preterm labor. Journal of Obstetrics and Gynaecology of India1991;41(6):765‐7. ">George 1991</a>; <a href="./references#CD002255-bbs2-0012" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169(4):960‐4. MoralesWJ , GlockD . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375. ">Glock 1993</a>; <a href="./references#CD002255-bbs2-0013" title="JajuPB , DhabadiVB . Nifedipine versus ritodrine for suppression of preterm labor and analysis of side effects. Journal of Obstetrics and Gynecology of India2011;61(5):534‐7. ">Jaju 2011</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0015" title="JannetD , AbankwaA , GuyardB , CarbonneB , MarpeauL , MilliezJ . Nicardipine versus salbutamol in the treatment of premature labor. A prospective randomized study. European Journal of Obstetrics, Gynecology and Reproductive Biology1997;73(1):11‐6. ">Jannet 1997</a>; <a href="./references#CD002255-bbs2-0016" title="KaraM , YilmazE , AvciI , OgeT . Comparison of nifedipine with magnesium sulphate plus terbutaline for the treatment of preterm labor [Preterm eylem tedavisinde nifedipin ile magnezyum sulfat ve terbutalinin etkilerinin karsilastirilmasi]. Turk Jinekoloji ve Obstetrik Dernegi Dergisi2009;6(4):250‐6. ">Kara 2009</a>; <a href="./references#CD002255-bbs2-0017" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology and Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD002255-bbs2-0018" title="KashanianM , BahasadriS , ZolaliB . Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2011;113(3):192‐5. ">Kashanian 2011</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0021" title="KoseD , KaraosmanogluS , YenigucCT , YucesoyI , OzbenC , BaysalC . Efficacy and safety of nifedipin in the management of preterm labor. Jinekoloji Ve Obstetrik Dergisi1995;9:165‐70. ">Kose 1995</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0023" title="LaohapojanartN , SoorapanS , WacharaprechanontT , RatanajamitC . Safety and efficacy of oral nifedipine versus terbutaline injection in preterm labour. Journal of the Medical Association of Thailand2007;90(11):2462‐7. ">Laohapojanart 2007</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0026" title="MawaldiL , DuminyP , TamimH . Terbutaline versus nifedipine for prolongation of pregnancy in patients with preterm labor. International Journal of Gynecology and Obstetrics2008;100:65‐8. ">Mawaldi 2008</a>; <a href="./references#CD002255-bbs2-0028" title="PadovaniTR , LopesLC . Nifedipine and terbutaline: comparative study of effectiveness and safety in preventing preterm labor. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S761. ">Padovani 2012</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0030" title="RayamajhiR , PratapK . A comparative study between nifedipine and isoxsuprine in the suppression of preterm labour. Kathmandu University Medical Journal2003;1(2):85‐90. ">Rayamajhi 2003</a>; <a href="./references#CD002255-bbs2-0031" title="ReadMD , WellbyDE . The use of a calcium antagonist (nifedipine) to suppress preterm labour. British Journal of Obstetrics and Gynaecology1986;93(9):933‐7. ">Read 1986</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD002255-bbs2-0033" title="TaherianA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulphate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>; <a href="./references#CD002255-bbs2-0034" title="TrabelsiK , Hadj TaibH , AmouriH , AbdennadheurW , Ben AmarH , KallelW , et al. Nicardipine versus salbutamol in the treatment of premature labor: comparison of their efficacy and side effects. Tunisie Medicale2008;86(1):43‐8. ">Trabelsi 2008</a>; <a href="./references#CD002255-bbs2-0035" title="ValdesE , SalinasH , ToledoV , LattesK , CuellarE , PeruccaE , et al. Nifedipine versus fenoterol in the management of preterm labor: a randomized, multicenter clinical study. Gynecologic &amp; Obstetric Investigation2012;74(2):109‐15. ">Valdes 2012</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>). Two studies randomised women to one of three groups; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>: nifedipine, indomethacin, and magnesium sulphate; and <a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a>: two different dosages of nifedipine or no treatment. For the <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a> study, only the subset of trial participants who did not receive prior betamimetic therapy (57 of 102 participants) was included. Another study (<a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>) compared high‐ with low‐dose nifedipine. </p> <section id="CD002255-sec-0077"> <h5 class="title">Participants</h5> <p>The participants included in these trials were reasonably homogeneous. The minimum gestational age at inclusion ranged from 20 to 30 weeks, and the maximum from 32 to 36 weeks. The mean gestational age at entry, when described, was between 28 and 33 weeks' gestation. Preterm labour was reasonably consistently defined across the trials, most excluding those women with a cervical dilatation of greater than 4 cm. Thirteen trials excluded women with cervical dilatation greater than 3 or 4 cm (<a href="./references#CD002255-bbs2-0001" title="Al‐QattanF , OmuAE , LabeebN . A prospective randomized study comparing nifedipine versus ritodrine for the suppression of preterm labour. Medical Principles &amp; Practice2000;9:164‐73. ">Al‐Qattan 2000</a>; <a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a>; <a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a>; <a href="./references#CD002255-bbs2-0013" title="JajuPB , DhabadiVB . Nifedipine versus ritodrine for suppression of preterm labor and analysis of side effects. Journal of Obstetrics and Gynecology of India2011;61(5):534‐7. ">Jaju 2011</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0016" title="KaraM , YilmazE , AvciI , OgeT . Comparison of nifedipine with magnesium sulphate plus terbutaline for the treatment of preterm labor [Preterm eylem tedavisinde nifedipin ile magnezyum sulfat ve terbutalinin etkilerinin karsilastirilmasi]. Turk Jinekoloji ve Obstetrik Dernegi Dergisi2009;6(4):250‐6. ">Kara 2009</a>; <a href="./references#CD002255-bbs2-0017" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology and Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD002255-bbs2-0018" title="KashanianM , BahasadriS , ZolaliB . Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2011;113(3):192‐5. ">Kashanian 2011</a>; <a href="./references#CD002255-bbs2-0021" title="KoseD , KaraosmanogluS , YenigucCT , YucesoyI , OzbenC , BaysalC . Efficacy and safety of nifedipin in the management of preterm labor. Jinekoloji Ve Obstetrik Dergisi1995;9:165‐70. ">Kose 1995</a>; <a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>; <a href="./references#CD002255-bbs2-0034" title="TrabelsiK , Hadj TaibH , AmouriH , AbdennadheurW , Ben AmarH , KallelW , et al. Nicardipine versus salbutamol in the treatment of premature labor: comparison of their efficacy and side effects. Tunisie Medicale2008;86(1):43‐8. ">Trabelsi 2008</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>; <a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a>) and two trials excluded women with cervical dilatation greater than 5 cm (<a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0033" title="TaherianA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulphate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>). Twenty trials excluded women with rupture of membranes (<a href="./references#CD002255-bbs2-0001" title="Al‐QattanF , OmuAE , LabeebN . A prospective randomized study comparing nifedipine versus ritodrine for the suppression of preterm labour. Medical Principles &amp; Practice2000;9:164‐73. ">Al‐Qattan 2000</a>; <a href="./references#CD002255-bbs2-0004" title="BraceroLA , LeikenE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:77. BraceroLA , LeikinE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. American Journal of Perinatology1991;8(6):365‐9. ">Bracero 1991</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0010" title="Garcia‐VelascoJA , Gonzalez GonzalezA . A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. International Journal of Gynaecology and Obstetrics1998;61:239‐44. ">Garcia‐Velasco 1998</a>; <a href="./references#CD002255-bbs2-0011" title="GeorgeSS , GeorgeK , JairajP . A randomized controlled study of nifedipine and isoxuprine in the treatment of preterm labor. Journal of Obstetrics and Gynaecology of India1991;41(6):765‐7. ">George 1991</a>; <a href="./references#CD002255-bbs2-0012" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169(4):960‐4. MoralesWJ , GlockD . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375. ">Glock 1993</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0015" title="JannetD , AbankwaA , GuyardB , CarbonneB , MarpeauL , MilliezJ . Nicardipine versus salbutamol in the treatment of premature labor. A prospective randomized study. European Journal of Obstetrics, Gynecology and Reproductive Biology1997;73(1):11‐6. ">Jannet 1997</a>; <a href="./references#CD002255-bbs2-0016" title="KaraM , YilmazE , AvciI , OgeT . Comparison of nifedipine with magnesium sulphate plus terbutaline for the treatment of preterm labor [Preterm eylem tedavisinde nifedipin ile magnezyum sulfat ve terbutalinin etkilerinin karsilastirilmasi]. Turk Jinekoloji ve Obstetrik Dernegi Dergisi2009;6(4):250‐6. ">Kara 2009</a>; <a href="./references#CD002255-bbs2-0017" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology and Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD002255-bbs2-0018" title="KashanianM , BahasadriS , ZolaliB . Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2011;113(3):192‐5. ">Kashanian 2011</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0023" title="LaohapojanartN , SoorapanS , WacharaprechanontT , RatanajamitC . Safety and efficacy of oral nifedipine versus terbutaline injection in preterm labour. Journal of the Medical Association of Thailand2007;90(11):2462‐7. ">Laohapojanart 2007</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0026" title="MawaldiL , DuminyP , TamimH . Terbutaline versus nifedipine for prolongation of pregnancy in patients with preterm labor. International Journal of Gynecology and Obstetrics2008;100:65‐8. ">Mawaldi 2008</a>; <a href="./references#CD002255-bbs2-0031" title="ReadMD , WellbyDE . The use of a calcium antagonist (nifedipine) to suppress preterm labour. British Journal of Obstetrics and Gynaecology1986;93(9):933‐7. ">Read 1986</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>) and 10 trials included twin pregnancies (<a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0017" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology and Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0026" title="MawaldiL , DuminyP , TamimH . Terbutaline versus nifedipine for prolongation of pregnancy in patients with preterm labor. International Journal of Gynecology and Obstetrics2008;100:65‐8. ">Mawaldi 2008</a>; <a href="./references#CD002255-bbs2-0030" title="RayamajhiR , PratapK . A comparative study between nifedipine and isoxsuprine in the suppression of preterm labour. Kathmandu University Medical Journal2003;1(2):85‐90. ">Rayamajhi 2003</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>). All trials excluded those women who had contra‐indications to either CCB or to betamimetics. The standard contra‐indications for tocolysis were reported as exclusion criteria in the majority of included trials, i.e. fetal distress, chorioamnionitis, severe pre‐eclampsia/eclampsia, and placental abruption. </p> </section> <section id="CD002255-sec-0078"> <h5 class="title">Tocolysis</h5> <p>Two types of CCBs were captured in this review: nifedipine and nicardipine. Of the 38 studies, only three trials of 261 women used nicardipine (<a href="./references#CD002255-bbs2-0015" title="JannetD , AbankwaA , GuyardB , CarbonneB , MarpeauL , MilliezJ . Nicardipine versus salbutamol in the treatment of premature labor. A prospective randomized study. European Journal of Obstetrics, Gynecology and Reproductive Biology1997;73(1):11‐6. ">Jannet 1997</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0034" title="TrabelsiK , Hadj TaibH , AmouriH , AbdennadheurW , Ben AmarH , KallelW , et al. Nicardipine versus salbutamol in the treatment of premature labor: comparison of their efficacy and side effects. Tunisie Medicale2008;86(1):43‐8. ">Trabelsi 2008</a>). Thirty‐five trials (3275 women) compared CCBs with other tocolytic agents (<a href="./references#CD002255-bbs2-0001" title="Al‐QattanF , OmuAE , LabeebN . A prospective randomized study comparing nifedipine versus ritodrine for the suppression of preterm labour. Medical Principles &amp; Practice2000;9:164‐73. ">Al‐Qattan 2000</a>; <a href="./references#CD002255-bbs2-0002" title="AmorimMM , LippoLA , CostaAA , CoutinhoIC , SouzaAS . Transdermal nitroglycerin versus oral nifedipine administration for tocolysis: a randomized clinical trial [Nitroglicerina transdermica versus nifedipina oral para inibicao do trabalho de parto prematuro: ensaio clinico randomizado]. Revista Brasileira de Ginecologia e Obstetricia2009;31(11):552‐8. ">Amorim 2009</a>; <a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a>; <a href="./references#CD002255-bbs2-0004" title="BraceroLA , LeikenE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:77. BraceroLA , LeikinE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. American Journal of Perinatology1991;8(6):365‐9. ">Bracero 1991</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0006" title="FanL , WuGF , HuangXH . The effect of calcium entry on the management of preterm labor ‐ a randomized controlled study. Chinese Journal of Practical Gynecology and Obstetrics2003;19(2):87‐9. ">Fan 2003</a>; <a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a>; <a href="./references#CD002255-bbs2-0010" title="Garcia‐VelascoJA , Gonzalez GonzalezA . A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. International Journal of Gynaecology and Obstetrics1998;61:239‐44. ">Garcia‐Velasco 1998</a>; <a href="./references#CD002255-bbs2-0011" title="GeorgeSS , GeorgeK , JairajP . A randomized controlled study of nifedipine and isoxuprine in the treatment of preterm labor. Journal of Obstetrics and Gynaecology of India1991;41(6):765‐7. ">George 1991</a>; <a href="./references#CD002255-bbs2-0012" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169(4):960‐4. MoralesWJ , GlockD . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375. ">Glock 1993</a>; <a href="./references#CD002255-bbs2-0013" title="JajuPB , DhabadiVB . Nifedipine versus ritodrine for suppression of preterm labor and analysis of side effects. Journal of Obstetrics and Gynecology of India2011;61(5):534‐7. ">Jaju 2011</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0016" title="KaraM , YilmazE , AvciI , OgeT . Comparison of nifedipine with magnesium sulphate plus terbutaline for the treatment of preterm labor [Preterm eylem tedavisinde nifedipin ile magnezyum sulfat ve terbutalinin etkilerinin karsilastirilmasi]. Turk Jinekoloji ve Obstetrik Dernegi Dergisi2009;6(4):250‐6. ">Kara 2009</a>; <a href="./references#CD002255-bbs2-0017" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology and Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD002255-bbs2-0018" title="KashanianM , BahasadriS , ZolaliB . Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2011;113(3):192‐5. ">Kashanian 2011</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0021" title="KoseD , KaraosmanogluS , YenigucCT , YucesoyI , OzbenC , BaysalC . Efficacy and safety of nifedipin in the management of preterm labor. Jinekoloji Ve Obstetrik Dergisi1995;9:165‐70. ">Kose 1995</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0023" title="LaohapojanartN , SoorapanS , WacharaprechanontT , RatanajamitC . Safety and efficacy of oral nifedipine versus terbutaline injection in preterm labour. Journal of the Medical Association of Thailand2007;90(11):2462‐7. ">Laohapojanart 2007</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0026" title="MawaldiL , DuminyP , TamimH . Terbutaline versus nifedipine for prolongation of pregnancy in patients with preterm labor. International Journal of Gynecology and Obstetrics2008;100:65‐8. ">Mawaldi 2008</a>; <a href="./references#CD002255-bbs2-0028" title="PadovaniTR , LopesLC . Nifedipine and terbutaline: comparative study of effectiveness and safety in preventing preterm labor. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S761. ">Padovani 2012</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0030" title="RayamajhiR , PratapK . A comparative study between nifedipine and isoxsuprine in the suppression of preterm labour. Kathmandu University Medical Journal2003;1(2):85‐90. ">Rayamajhi 2003</a>; <a href="./references#CD002255-bbs2-0031" title="ReadMD , WellbyDE . The use of a calcium antagonist (nifedipine) to suppress preterm labour. British Journal of Obstetrics and Gynaecology1986;93(9):933‐7. ">Read 1986</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD002255-bbs2-0033" title="TaherianA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulphate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>; <a href="./references#CD002255-bbs2-0035" title="ValdesE , SalinasH , ToledoV , LattesK , CuellarE , PeruccaE , et al. Nifedipine versus fenoterol in the management of preterm labor: a randomized, multicenter clinical study. Gynecologic &amp; Obstetric Investigation2012;74(2):109‐15. ">Valdes 2012</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>; <a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a>). Twenty‐three of these trials (1793 women) used betamimetic agents as the other tocolytic. The largest trial (<a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>, 276 women and 317 neonates) randomised participants to one of three arms: nifedipine, indomethacin, or magnesium sulphate. Initial tocolytic therapy with nifedipine was administered orally or sublingually, as either capsules or tablets (whole, or crushed and dissolved in water). Dosage varied from 30 mg/day to 160 mg/day until uterine contractions stopped. <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a> used a higher dose of nifedipine than most of the included trials (up to 40 mg in the first hour). Twenty‐three trials continued oral nifedipine after the initial treatment. Four trials (<a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0004" title="BraceroLA , LeikenE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:77. BraceroLA , LeikinE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. American Journal of Perinatology1991;8(6):365‐9. ">Bracero 1991</a>; <a href="./references#CD002255-bbs2-0028" title="PadovaniTR , LopesLC . Nifedipine and terbutaline: comparative study of effectiveness and safety in preventing preterm labor. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S761. ">Padovani 2012</a>; <a href="./references#CD002255-bbs2-0033" title="TaherianA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulphate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>) did not report the total duration of treatment (one of these (<a href="./references#CD002255-bbs2-0028" title="PadovaniTR , LopesLC . Nifedipine and terbutaline: comparative study of effectiveness and safety in preventing preterm labor. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S761. ">Padovani 2012</a>) was reported as an abstract only). Thirteen trials used ritodrine as the other tocolytic. Ritodrine was usually started at 50 µg/minute except for <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a><a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a> and <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>, which started at a loading dose of 100 to 200 µg/minute and the rate was increased up to 300 or 350 µg/minute until uterine contractions stopped. <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a> started ritodrine at a loading dose of 383 µg/minute and gradually decreased to a minimum of 100 µg/minute. Three trials compared nifedipine and isoxsuprine (<a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a>; <a href="./references#CD002255-bbs2-0011" title="GeorgeSS , GeorgeK , JairajP . A randomized controlled study of nifedipine and isoxuprine in the treatment of preterm labor. Journal of Obstetrics and Gynaecology of India1991;41(6):765‐7. ">George 1991</a>; <a href="./references#CD002255-bbs2-0030" title="RayamajhiR , PratapK . A comparative study between nifedipine and isoxsuprine in the suppression of preterm labour. Kathmandu University Medical Journal2003;1(2):85‐90. ">Rayamajhi 2003</a>), seven trials compared nifedipine and magnesium sulphate (MgSO4) (<a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0012" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169(4):960‐4. MoralesWJ , GlockD . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375. ">Glock 1993</a>; <a href="./references#CD002255-bbs2-0016" title="KaraM , YilmazE , AvciI , OgeT . Comparison of nifedipine with magnesium sulphate plus terbutaline for the treatment of preterm labor [Preterm eylem tedavisinde nifedipin ile magnezyum sulfat ve terbutalinin etkilerinin karsilastirilmasi]. Turk Jinekoloji ve Obstetrik Dernegi Dergisi2009;6(4):250‐6. ">Kara 2009</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0033" title="TaherianA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulphate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>); two trials compared nifedipine and oxytocin receptor antagonists (ORA), both using atosiban (<a href="./references#CD002255-bbs2-0017" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology and Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>); four trials compared nifedipine and terbutaline (<a href="./references#CD002255-bbs2-0023" title="LaohapojanartN , SoorapanS , WacharaprechanontT , RatanajamitC . Safety and efficacy of oral nifedipine versus terbutaline injection in preterm labour. Journal of the Medical Association of Thailand2007;90(11):2462‐7. ">Laohapojanart 2007</a>; <a href="./references#CD002255-bbs2-0026" title="MawaldiL , DuminyP , TamimH . Terbutaline versus nifedipine for prolongation of pregnancy in patients with preterm labor. International Journal of Gynecology and Obstetrics2008;100:65‐8. ">Mawaldi 2008</a>; <a href="./references#CD002255-bbs2-0028" title="PadovaniTR , LopesLC . Nifedipine and terbutaline: comparative study of effectiveness and safety in preventing preterm labor. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S761. ">Padovani 2012</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>); one trial compared nifedipine and glyceryl trinitrate (GTN) patch (<a href="./references#CD002255-bbs2-0002" title="AmorimMM , LippoLA , CostaAA , CoutinhoIC , SouzaAS . Transdermal nitroglycerin versus oral nifedipine administration for tocolysis: a randomized clinical trial [Nitroglicerina transdermica versus nifedipina oral para inibicao do trabalho de parto prematuro: ensaio clinico randomizado]. Revista Brasileira de Ginecologia e Obstetricia2009;31(11):552‐8. ">Amorim 2009</a>); two trials compared nifedipine and non‐steroidal anti‐inflammatory drugs (NSAID), both using indomethacin suppository (<a href="./references#CD002255-bbs2-0018" title="KashanianM , BahasadriS , ZolaliB . Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2011;113(3):192‐5. ">Kashanian 2011</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>); and one trial compared nifedipine and fenoterol (<a href="./references#CD002255-bbs2-0035" title="ValdesE , SalinasH , ToledoV , LattesK , CuellarE , PeruccaE , et al. Nifedipine versus fenoterol in the management of preterm labor: a randomized, multicenter clinical study. Gynecologic &amp; Obstetric Investigation2012;74(2):109‐15. ">Valdes 2012</a>). </p> <p>Two trials compared intravenous nicardipine with salbutamol (<a href="./references#CD002255-bbs2-0015" title="JannetD , AbankwaA , GuyardB , CarbonneB , MarpeauL , MilliezJ . Nicardipine versus salbutamol in the treatment of premature labor. A prospective randomized study. European Journal of Obstetrics, Gynecology and Reproductive Biology1997;73(1):11‐6. ">Jannet 1997</a>; <a href="./references#CD002255-bbs2-0034" title="TrabelsiK , Hadj TaibH , AmouriH , AbdennadheurW , Ben AmarH , KallelW , et al. Nicardipine versus salbutamol in the treatment of premature labor: comparison of their efficacy and side effects. Tunisie Medicale2008;86(1):43‐8. ">Trabelsi 2008</a>). The doses used were 6 mg/hour and 4 mg/hour respectively. <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a> used oral nicardipine, at a dose of 40 mg orally then 20 mg 2 hour as necessary up to three doses, with magnesium sulphate (MgSO4). One trial (<a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>) compared a high dose of nifedipine (20 mg sublingual repeated in 30 minutes followed by 120 to 160 mg slow release nifedipine daily for 48 hours) with low‐dose nifedipine (10 mg repeated every 15 minutes to a maximum of four doses followed by 60 to 80 mg slow release daily for 48 hours and 60 mg up to 36 weeks). </p> </section> <section id="CD002255-sec-0079"> <h5 class="title">Outcome measures</h5> <p>There was some inconsistency across the trials with respect to the way in which outcomes were reported. The clinically important outcome of delay in delivery for greater than or equal to 48 hours was reported in 31 of the 38 included trials, discontinuation of treatment because of adverse effects was reported in 21 trials, and perinatal mortality in 24 trials. Extremely preterm birth (before completion of 28 weeks of gestation) was reported in two trials, very preterm birth (before completion of 34 weeks of gestation) in 12 trials, and preterm birth (before completion of 37 weeks of gestation) in 21 trials. With the exception of neonatal mortality, neonatal outcomes were less consistently reported, and definitions were often lacking (e.g. criteria for diagnosing respiratory distress syndrome (RDS), sepsis or for admission to intensive care nursery.<br/> <br/> The neonatal outcomes of the trial of <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a> were reported more comprehensively in a subsequent publication, with precise definitions. This second report used a more stringent definition for admission to the NICU than the one used in the initial report. Because the other trials used a more general definition (usually not defined, but presumably any admission to intensive care nursery) in order to maintain consistency, we have chosen to use the data from the primary publication for <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>. Some degree of assessment bias is possible for the neonatal morbidity indices in the trials because neonatal assessment was undertaken by clinicians not blinded to maternal treatment allocation. </p> <p>Longer‐term neonatal assessment was undertaken in only two trials; <a href="./references#CD002255-bbs2-0090" title="HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an International Journal of Obstetrics and Gynaecology2005;113:324‐31. ">Houtzager 2005</a> report nine to 12 year follow‐up data by survey for children enrolled in <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997.</a> Questionnaires were completed by the parent, child and teacher. The child’s motor functioning was obtained from the parent using the Movement Assessment Battery for Children (Movement ABC) (<a href="./references#CD002255-bbs2-0087" title="HendersenSE , SugdenDA . Movement Assessment Battery for Children. Lisse, The Netherlands: Handleiding: Swets &amp; Zeitlinger, 1998. ">Hendersen 1998</a>) checklist (Dutch version) (<a href="./references#CD002255-bbs2-0111" title="Smits‐EngelsmanaBCM , HendersonSE , MichelsCGJ . The assessment of children with developmental coordination disorders in the Netherlands: The relationship between the Movement Assessment Battery for Children and the Körperkoordinations Test für Kinder. Human Movement Science1998;17(4‐5):699‐709. ">Smits‐Engelsman 1998</a>). The total Movement ABC score was used, with a high score referring to less favourable motor functioning. Behavioural–emotional functioning was assessed using the Dutch version of the Child Behavior Check List (CBCL) (<a href="./references#CD002255-bbs2-0072" title="AchenbackTM . Manual for the Child Behaviour Checklist and Revised Child Behaviour Profile. Burlington VT: Department of Psychiatry, University of Vermont, 1983. ">Achenbach TM</a>) to be completed by the parent. The child’s teacher completed the Teacher Report Form (TRF) (<a href="./references#CD002255-bbs2-0119" title="VerhulstFC , Van derEndeJ , KootHM . Hanleiding voor de Teacher report (TRF); Nederlandse versie. Afdeling Kinder‐en Jeugdpsychiatrie, Sophia Kinder Zeikenhuis/Acadeisch Ziekenhuis Rotterdam/Erasmus Universitiet Rotterdam1997. ">Verhulst 1997</a>). The child's quality of life (QoL) was assessed using the Dutch TNO AZL Children's Quality of Life Questionnare (TACQOL) (<a href="./references#CD002255-bbs2-0120" title="VogelsT , VerripsGH , Verloof‐VanhorickSP , FekkesM , KamphiusRP , KoopmanHM , et al. Measuring health related quality of life in children: the development of the TACQOL parent form. Qual Life Res1998;7:457‐65. ">Vogels 1998</a>; <a href="./references#CD002255-bbs2-0121" title="VogelsT , VerripsGH , KoopmanHM , TheunissenNCM , FekkesM , KamphiusRP . TACQOL Manual: Parent Form and Child Form. Leiden Center for Child Health and Paediatrics LUMC‐TNO. Leiden: TNO Prevention and Health and the Leiden University Medical Centre, 2000. ">Vogels 2000</a>). Further, women completed the Dutch Nijmegen Parental Distress Index ‐ Short version (NOSI‐K) (<a href="./references#CD002255-bbs2-0071" title="AbidinRR , deBrockAJLL , GerrisJRM , VermulstAA . NOSI: Nijmeegse Ouderlijke Stress Index. Swets en Zeitlinger b.v, Lisse, Switzerland, 1992. ">Abidin 1992</a>) via a survey to assess parenting distress. Additional information about the child’s school level, family demographics and psychosocial care was obtained from the survey of women. In this review, we have included the outcomes of motor quality, behavioural–emotional functioning, parent stress by parent report and the child's quality of life reported by the child. <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a> reported two‐year outcomes for children. However, we were not able to include these outcomes as data were not presented in a suitable format and further details have been requested from the authors. </p> <p>Please <i>see</i><a href="./references#CD002255-sec-0131" title="">Characteristics of included studies</a> for further details. </p> </section> <section id="CD002255-sec-0080"> <h5 class="title">Other unit of analysis issues</h5> <p>One study (<a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>, 276 women and 317 neonates) randomised participants to one of three arms: nifedipine, indomethacin, or magnesium sulphate. For the comparison of CCB with other tocolytic agents (subgrouped by type), for all reported outcomes we divided the number of events and total participants by two in the CCB arms. </p> </section> </section> <section id="CD002255-sec-0081"> <h4 class="title">Excluded studies</h4> <p>Seven trials were excluded on the basis of quasi‐random allocation to treatment (<a href="./references#CD002255-bbs2-0039" title="Al‐OmariWR , Al‐ShammaaHB , Al‐TikritiEM , AhmedKW . Atosiban and nifedipine in acute tocolysis: A comparative study. European Journal of Obstetrics and Gynecology and Reproductive Biology2006;128:129‐34. Al‐OmariWR , Al‐TikritiE , Al‐ShammaH . Atosiban and nifedipine in acute tocolysis, comparative study [abstract]. XVIIIth European Congress of Obstetrics and Gynaecology; 2004 May 12‐15; Athens, Greece. 2004:103. ">Al‐Omari 2006</a>; <a href="./references#CD002255-bbs2-0044" title="Dunstan‐BooneG , BondA , ThorntonYS . A comparison of verapamil vs ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990; Houston, Texas, USA, 1990:83. 1990:83. ">Dunstan‐Boone 1990</a>; <a href="./references#CD002255-bbs2-0047" title="JunejoN , MumtazF , UnarBA . Comparison of salbutamol and nifedipine as a tocolytic agent in the treatment of preterm labor. Journal of Liaquat University of Medical and Health Sciences2008;7(2):115‐9. ">Junejo 2008</a>; <a href="./references#CD002255-bbs2-0049" title="MaitraN , ChristianV , KavishvarA . Tocolytic efficacy of nifedipine versus ritodrine in preterm labor. International Journal of Gynecology &amp; Obstetrics2007;97(2):147‐8. MaitraN , ChristianV , VermaRN , DesaiVA . Maternal and fetal cardiovascular side effects of nifedipine and ritodrine used as tocolytics. Journal of Obstetrics and Gynaecology of India2007;57(2):131‐4. ">Maitra 2007</a>; <a href="./references#CD002255-bbs2-0050" title="MalikKK . Comparison of nifedipine with salbutamol as tocolytic agents in preterm labour. Biomedica2007;23:111‐5. ">Malik 2007</a>; <a href="./references#CD002255-bbs2-0052" title="PapadopoulosV , DecavalasG , TzingounisV . Nifedipine versus ritodrine in the treatment of preterm labor. Acta Obstetricia et Gynecologica Scandinavica Supplement1997;76(167:1):88. ">Papadopoulos 1997</a>; <a href="./references#CD002255-bbs2-0056" title="SmithCS , WoodlandMB . Clinical comparison of oral nifedipine and subcutaneous terbutaline for initial tocolysis. American Journal of Perinatology1993;10:280‐4. WoodlandMB , SmithC , ByersJ , BologneseR , WeinerS . Clinical comparison of oral nifedipine and subcutaneous terbutaline use for initial tocolysis. Proceedings of 10th Annual meeting of Society of Perinatal Obstetricans; 1990; Houston, Texas, USA. 1990:523. ">Smith 1993</a>). Ten studies were excluded as they did not fulfil the intervention inclusion criteria as follows: did not use a CCB (<a href="./references#CD002255-bbs2-0040" title="BreartG , SureauC , Rumeau‐RouquetteC . A study of the comparative efficiency of ifenprodil and ritodrine in the treatment of threatening premature labour [translation]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1979;8(3):261‐3. ">Breart 1979</a>; <a href="./references#CD002255-bbs2-0055" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG: an International Journal of Obstetrics and Gynaecology2006;113(11):1228‐34. ">Shim 2006</a>); a pharmacokinetic study of nifedipine (<a href="./references#CD002255-bbs2-0048" title="JuonAM , Kühn‐VeltenWN , BurkhardtT , KrahenmannF , ZimmermannR , vonMandachU . Nifedipine gastrointestinal therapeutic system (GITS) as an alternative to slow‐release for tocolysis‐‐tolerance and pharmacokinetic profile. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2008;140:27‐32. ">Juon 2008</a>); compared bed rest or 17‐OH progesterone injection to nifedipine (<a href="./references#CD002255-bbs2-0042" title="ChawanpaiboonS , PimolK , SirisomboonR . Comparison of success rate of nifedipine, progesterone, and bed rest for inhibiting uterine contraction in threatened preterm labor. Journal of Obstetrics and Gynaecology Research2011;37(7):787‐91. ChawanpaiboonS , SutantawibulA , PimolK , SirisomboonR , WorapitaksanondS . Preliminary study: Comparison of the efficacy of progesterone and nifedipine in inhibiting threatened preterm labour in Siriraj Hospital. Thai Journal of Obstetrics and Gynaecology2009;17:23‐9. ">Chawanpaiboon 2011</a>); compared atosiban with clinician choice of one or more other tocolytics (<a href="./references#CD002255-bbs2-0046" title="HussleinP , Cabero RouraL , DudenhausenJW , HelmerH , FrydmanR , RizzoN , et al. Atosiban versus usual care for the management of preterm labor. Journal of Perinatal Medicine2007;35(4):305‐13. ">Husslein 2007</a>); psychotherapeutic interventions for women in preterm labour, while using nifedipine as choice of tocolysis (<a href="./references#CD002255-bbs2-0043" title="DasariP , KodencheryMM . Psychological factors in preterm labor and psychotherapeutic intervention. International Journal of Gynaecology &amp; Obstetrics2007;97(3):196‐7. ">Dasari 2007</a>); the addition of a CCB for women receiving tocolysis with a betamimetic agent (<a href="./references#CD002255-bbs2-0054" title="Rodriguez‐EscuderoFJ , ArangurenG , BenitoJA . Verapamil to inhibit the cardiovascular side effects of ritodrine. International Journal of Gynecology and Obstetrics1981;19:333‐6. ">Rodriguez‐Escudero 1981</a>; <a href="./references#CD002255-bbs2-0053" title="PiovanoA , CarboniF , CasaleO , D'AngeloA , OsesA . Calcium antagonism in the control of adverse reactions during utero‐inhibition. Archives of Gynecology1985;237 Suppl 1:98. ">Piovano 1985</a>); maintenance therapy of women following successful tocolysis (<a href="./references#CD002255-bbs2-0041" title="CarrDB , ClarkAL , KernekK , SpinnatoJA . Maintenance oral nifedipine for preterm labor: a randomised clinical trial. American Journal of Obstetrics and Gynecology1999;181(4):822‐7. ">Carr 1993</a>; <a href="./references#CD002255-bbs2-0045" title="El‐SayedYY , HolbrookRHJr , GibsonR , ChitkaraU , DruzinML , BabaD . Diltiazem for maintenance tocolysis of preterm labor: comparison to nifedipine in a randomized trial. Journal of Maternal‐Fetal Medicine1998;7(5):217‐21. ">El‐Sayed 1998</a>). One study was excluded (<a href="./references#CD002255-bbs2-0051" title="MeyerWR , RandallHW , GravesWL . Nifedipine versus ritodrine for suppressing preterm labor. Journal of Reproductive Medicine1990;35:649‐53. ">Meyer 1990</a>) as women were enrolled only after subcutaneous terbutaline failed to stop regular uterine contractions and this may have introduced a systematic bias favouring nifedipine since only women who did not respond to the beta‐adrenergic agonist were admitted to the trial. </p> <p>Please see <a href="./references#CD002255-sec-0132" title="">Characteristics of excluded studies</a> for further details. </p> </section> </section> <section id="CD002255-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall the quality of the included trials was fair. Refer to <a href="./references#CD002255-sec-0131" title="">Characteristics of included studies</a> for further details and to <a href="#CD002255-fig-0001">Figure 1</a> and <a href="#CD002255-fig-0002">Figure 2</a> for a summary of 'Risk of bias' assessments. </p> <div class="figure" id="CD002255-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002255-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD002255-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002255-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002255-sec-0083"> <h4 class="title">Allocation</h4> <p>The randomisation sequence generation was judged as adequate in 22 of the 38 included studies (<a href="./references#CD002255-bbs2-0001" title="Al‐QattanF , OmuAE , LabeebN . A prospective randomized study comparing nifedipine versus ritodrine for the suppression of preterm labour. Medical Principles &amp; Practice2000;9:164‐73. ">Al‐Qattan 2000</a>; <a href="./references#CD002255-bbs2-0002" title="AmorimMM , LippoLA , CostaAA , CoutinhoIC , SouzaAS . Transdermal nitroglycerin versus oral nifedipine administration for tocolysis: a randomized clinical trial [Nitroglicerina transdermica versus nifedipina oral para inibicao do trabalho de parto prematuro: ensaio clinico randomizado]. Revista Brasileira de Ginecologia e Obstetricia2009;31(11):552‐8. ">Amorim 2009</a>; <a href="./references#CD002255-bbs2-0004" title="BraceroLA , LeikenE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:77. BraceroLA , LeikinE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. American Journal of Perinatology1991;8(6):365‐9. ">Bracero 1991</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0010" title="Garcia‐VelascoJA , Gonzalez GonzalezA . A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. International Journal of Gynaecology and Obstetrics1998;61:239‐44. ">Garcia‐Velasco 1998</a>; <a href="./references#CD002255-bbs2-0011" title="GeorgeSS , GeorgeK , JairajP . A randomized controlled study of nifedipine and isoxuprine in the treatment of preterm labor. Journal of Obstetrics and Gynaecology of India1991;41(6):765‐7. ">George 1991</a>; <a href="./references#CD002255-bbs2-0017" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology and Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD002255-bbs2-0018" title="KashanianM , BahasadriS , ZolaliB . Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2011;113(3):192‐5. ">Kashanian 2011</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0023" title="LaohapojanartN , SoorapanS , WacharaprechanontT , RatanajamitC . Safety and efficacy of oral nifedipine versus terbutaline injection in preterm labour. Journal of the Medical Association of Thailand2007;90(11):2462‐7. ">Laohapojanart 2007</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD002255-bbs2-0033" title="TaherianA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulphate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>; <a href="./references#CD002255-bbs2-0035" title="ValdesE , SalinasH , ToledoV , LattesK , CuellarE , PeruccaE , et al. Nifedipine versus fenoterol in the management of preterm labor: a randomized, multicenter clinical study. Gynecologic &amp; Obstetric Investigation2012;74(2):109‐15. ">Valdes 2012</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>) and therefore assessed as having a low risk of selection bias. In the remaining 16 studies the randomisation sequence generation process was unclear. </p> <p>Allocation to treatment was adequately concealed in 14 studies and therefore assessed as having a low risk of selection bias (<a href="./references#CD002255-bbs2-0004" title="BraceroLA , LeikenE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:77. BraceroLA , LeikinE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. American Journal of Perinatology1991;8(6):365‐9. ">Bracero 1991</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0012" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169(4):960‐4. MoralesWJ , GlockD . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375. ">Glock 1993</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD002255-bbs2-0034" title="TrabelsiK , Hadj TaibH , AmouriH , AbdennadheurW , Ben AmarH , KallelW , et al. Nicardipine versus salbutamol in the treatment of premature labor: comparison of their efficacy and side effects. Tunisie Medicale2008;86(1):43‐8. ">Trabelsi 2008</a>; <a href="./references#CD002255-bbs2-0035" title="ValdesE , SalinasH , ToledoV , LattesK , CuellarE , PeruccaE , et al. Nifedipine versus fenoterol in the management of preterm labor: a randomized, multicenter clinical study. Gynecologic &amp; Obstetric Investigation2012;74(2):109‐15. ">Valdes 2012</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>). In the remaining trials the allocation process was unclear. </p> </section> <section id="CD002255-sec-0084"> <h4 class="title">Blinding</h4> <p>Blinding of the intervention (performance bias) was attempted in only one of the included studies (<a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a>) ‐ the only placebo controlled trial. For the remaining trials, the lack of blinding of the intervention may be, in part, as a result of the difficulties with adequately blinding such interventions (i.e. presentation of the intervention as either oral versus intravenous and the well‐known side effects of certain interventions). For blinding of outcome measures (detection bias), all trials were deemed as having low risk of bias for objective outcomes (interval between trial entry and birth, gestation at birth (preterm birth and mean gestational age), perinatal mortality, stillbirth, and neonatal death). One trial (<a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>) used blinded assessment of all outcome measures and was considered to have low risk of detection bias for both objective and subjective outcome measures. All other trials were considered to be at high risk of detection bias for subjective outcome measures (i.e. maternal and neonatal morbidity measures). </p> </section> <section id="CD002255-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>The majority of the studies had minimal or no attrition and were therefore assessed as having a low risk of attrition bias. To enable analysis by intention‐to‐treat, additional information was sought from the investigators of 13 included studies (<a href="./references#CD002255-bbs2-0004" title="BraceroLA , LeikenE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:77. BraceroLA , LeikinE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. American Journal of Perinatology1991;8(6):365‐9. ">Bracero 1991</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0010" title="Garcia‐VelascoJA , Gonzalez GonzalezA . A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. International Journal of Gynaecology and Obstetrics1998;61:239‐44. ">Garcia‐Velasco 1998</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0096" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. ">Nassar 2007</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0031" title="ReadMD , WellbyDE . The use of a calcium antagonist (nifedipine) to suppress preterm labour. British Journal of Obstetrics and Gynaecology1986;93(9):933‐7. ">Read 1986</a>; <a href="./references#CD002255-bbs2-0033" title="TaherianA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulphate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>) and data were provided and included for 11 of these studies (<a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0010" title="Garcia‐VelascoJA , Gonzalez GonzalezA . A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. International Journal of Gynaecology and Obstetrics1998;61:239‐44. ">Garcia‐Velasco 1998</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0096" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. ">Nassar 2007</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>). </p> </section> <section id="CD002255-sec-0086"> <h4 class="title">Selective reporting</h4> <p>Selective reporting was considered possible in one trial (<a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a>) where the outcomes of pregnancy prolongation for 48 hours and until 36 weeks were omitted from the results. In this trial, failure to achieve uterine relaxation or development of significant side effects in the mother or fetus was considered treatment "failure", and treatment "success" was only reported as the inverse of this. In 23 trials, we found no obvious evidence of reporting bias (<a href="./references#CD002255-bbs2-0001" title="Al‐QattanF , OmuAE , LabeebN . A prospective randomized study comparing nifedipine versus ritodrine for the suppression of preterm labour. Medical Principles &amp; Practice2000;9:164‐73. ">Al‐Qattan 2000</a>; <a href="./references#CD002255-bbs2-0002" title="AmorimMM , LippoLA , CostaAA , CoutinhoIC , SouzaAS . Transdermal nitroglycerin versus oral nifedipine administration for tocolysis: a randomized clinical trial [Nitroglicerina transdermica versus nifedipina oral para inibicao do trabalho de parto prematuro: ensaio clinico randomizado]. Revista Brasileira de Ginecologia e Obstetricia2009;31(11):552‐8. ">Amorim 2009</a>; <a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a>; <a href="./references#CD002255-bbs2-0004" title="BraceroLA , LeikenE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:77. BraceroLA , LeikinE , KirshenbaumN , TejaniN . Comparison of nifedipine and ritodrine for the treatment of preterm labor. American Journal of Perinatology1991;8(6):365‐9. ">Bracero 1991</a>; <a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0010" title="Garcia‐VelascoJA , Gonzalez GonzalezA . A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. International Journal of Gynaecology and Obstetrics1998;61:239‐44. ">Garcia‐Velasco 1998</a>; <a href="./references#CD002255-bbs2-0012" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169(4):960‐4. MoralesWJ , GlockD . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375. ">Glock 1993</a>; <a href="./references#CD002255-bbs2-0013" title="JajuPB , DhabadiVB . Nifedipine versus ritodrine for suppression of preterm labor and analysis of side effects. Journal of Obstetrics and Gynecology of India2011;61(5):534‐7. ">Jaju 2011</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0021" title="KoseD , KaraosmanogluS , YenigucCT , YucesoyI , OzbenC , BaysalC . Efficacy and safety of nifedipin in the management of preterm labor. Jinekoloji Ve Obstetrik Dergisi1995;9:165‐70. ">Kose 1995</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>;<a href="./references#CD002255-bbs2-0035" title="ValdesE , SalinasH , ToledoV , LattesK , CuellarE , PeruccaE , et al. Nifedipine versus fenoterol in the management of preterm labor: a randomized, multicenter clinical study. Gynecologic &amp; Obstetric Investigation2012;74(2):109‐15. ">Valdes 2012</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>) and judged these trials to be at low risk of bias. In the remaining trials it was unclear whether selective reporting bias was present. </p> <p>No obvious evidence of selective reporting bias was shown in funnel plots (<a href="#CD002255-fig-0003">Figure 3</a>; <a href="#CD002255-fig-0004">Figure 4</a>; <a href="#CD002255-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD002255-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), outcome: 2.1 Birth less than 48 hours after trial entry." data-id="CD002255-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), outcome: 2.1 Birth less than 48 hours after trial entry. </p> </div> </div> </div> <div class="figure" id="CD002255-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by agent), outcome: 2.3 Perinatal mortality." data-id="CD002255-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by agent), outcome: 2.3 Perinatal mortality. </p> </div> </div> </div> <div class="figure" id="CD002255-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), outcome: 2.9 Preterm birth (before completion of 37 weeks of gestation)." data-id="CD002255-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), outcome: 2.9 Preterm birth (before completion of 37 weeks of gestation). </p> </div> </div> </div> </section> <section id="CD002255-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <p>Sixteen studies were assessed as being at low risk of bias for other potential sources of bias based on baseline characteristics being similar between groups and no other bias apparent (<a href="./references#CD002255-bbs2-0005" title="CararachV , PalacioM , MartinezS , DeulofeuP , SanchezM , CoboT , et al. Nifedipine versus ritodrine for suppression of preterm labor: comparison of their efficacy and secondary effects. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;127(2):204‐8. MartinezS , ManauMD , VivesA , CarmonaF , DeulofeuP , CararachV . A prospective and randomized study about the use of calcium blockers vs betamimetics in preterm labour. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:Abstract no: 414. ">Cararach 2006</a>; <a href="./references#CD002255-bbs2-0007" title="FergusonJE , DysonDC , HolbrookRHJr , SchultzT , StevensonDK . Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. American Journal of Obstetrics and Gynecology1989;161(3):788‐95. FergusonJE , DysonDC , SchutzT , StevensonDK . A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. American Journal of Obstetrics and Gynecology1990;163(1 Pt 1):105‐11. FergusonJE , SchultzTE , StevensonDK . Neonatal bilirubin production after preterm labor tocolysis with nifedipine. Developmental Pharmacology Therapeutics1989;12(3):113‐7. ">Ferguson 1990</a>; <a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0010" title="Garcia‐VelascoJA , Gonzalez GonzalezA . A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. International Journal of Gynaecology and Obstetrics1998;61:239‐44. ">Garcia‐Velasco 1998</a>; <a href="./references#CD002255-bbs2-0012" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169(4):960‐4. MoralesWJ , GlockD . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375. ">Glock 1993</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0016" title="KaraM , YilmazE , AvciI , OgeT . Comparison of nifedipine with magnesium sulphate plus terbutaline for the treatment of preterm labor [Preterm eylem tedavisinde nifedipin ile magnezyum sulfat ve terbutalinin etkilerinin karsilastirilmasi]. Turk Jinekoloji ve Obstetrik Dernegi Dergisi2009;6(4):250‐6. ">Kara 2009</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>; <a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD002255-bbs2-0034" title="TrabelsiK , Hadj TaibH , AmouriH , AbdennadheurW , Ben AmarH , KallelW , et al. Nicardipine versus salbutamol in the treatment of premature labor: comparison of their efficacy and side effects. Tunisie Medicale2008;86(1):43‐8. ">Trabelsi 2008</a>; <a href="./references#CD002255-bbs2-0035" title="ValdesE , SalinasH , ToledoV , LattesK , CuellarE , PeruccaE , et al. Nifedipine versus fenoterol in the management of preterm labor: a randomized, multicenter clinical study. Gynecologic &amp; Obstetric Investigation2012;74(2):109‐15. ">Valdes 2012</a>; <a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>; <a href="./references#CD002255-bbs2-0037" title="WeerakulW , ChittacharoenA , SuthutvoravutS . Nifedipine versus terbutaline in management of preterm labor. International Journal of Gynecology and Obstetrics2002;76:311‐3. ">Weerakul 2002</a>). In the remaining 22 studies, the risk of other sources of bias was unclear. <a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a> reported that women in the groups were "well matched" on various characteristics at baseline but no data were provided. <a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a> also concluded that perinatal mortality was reduced by nifedipine, although this outcome was not reported in the results. This research article is housed on a website sponsored by a global pharmaceutical company. </p> <section id="CD002255-sec-0088"> <h5 class="title">Assessment of studies that included multiple pregnancies</h5> <p>In 10 studies women with a multiple pregnancy were eligible for entry (<a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a>; <a href="./references#CD002255-bbs2-0017" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology and Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0026" title="MawaldiL , DuminyP , TamimH . Terbutaline versus nifedipine for prolongation of pregnancy in patients with preterm labor. International Journal of Gynecology and Obstetrics2008;100:65‐8. ">Mawaldi 2008</a>; <a href="./references#CD002255-bbs2-0030" title="RayamajhiR , PratapK . A comparative study between nifedipine and isoxsuprine in the suppression of preterm labour. Kathmandu University Medical Journal2003;1(2):85‐90. ">Rayamajhi 2003</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>), although <a href="./references#CD002255-bbs2-0014" title="JankyE , LengJJ , CormierPH , SalamonR , MeynardJ . A randomized study of the treatment of threatened premature labor. Nifedipine versus ritodrine. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris)1990;19:478‐82. ">Janky 1990</a> did not appear to recruit any women with a multiple pregnancy. Of the nine studies that included twins or multiples, seven reported neonatal outcomes <a href="./references#CD002255-bbs2-0008" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor. American Journal of Obstetrics and Gynecology1992;166:446. FloydRC , McLaughlinBN , PerryKGJr , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5(1):25‐9. ">Floyd 1992</a>; <a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>; <a href="./references#CD002255-bbs2-0020" title="KoksCA , BrolmannHA , deKleineMJ , MangerPA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labor. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;77(2):171‐6. ">Koks 1998</a>; <a href="./references#CD002255-bbs2-0022" title="KupfermincM , LessingJB , PeyserMR . A comparative, prospective, randomized study of nifedipine vs ritodrine for suppressing preterm labor. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992 March 18‐21; San Antonio, Texas, USA. 1992:335. KupfermincM , LessingJB , YaronY , PeyserMR . Nifedipine versus ritodrine for suppression of preterm labour. British Journal of Obstetrics and Gynaecology1993;100(12):1090‐4. ">Kupferminc 1993</a>; <a href="./references#CD002255-bbs2-0025" title="LyellD , PennA , CaugheyA , KogutE , McClellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐1. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor. Obstetrics &amp; Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD002255-bbs2-0030" title="RayamajhiR , PratapK . A comparative study between nifedipine and isoxsuprine in the suppression of preterm labour. Kathmandu University Medical Journal2003;1(2):85‐90. ">Rayamajhi 2003</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>. Where possible, we adjusted neonatal outcomes for clustering to take into account the non‐independence of babies from the same pregnancy. Statistics were adjusted according to methods described in the <i>Handbook</i> (<a href="./references#CD002255-bbs2-0088" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and using an estimate of the ICC of 0.2, as recommended by <a href="./references#CD002255-bbs2-0124" title="YellandLN , SalteraAB , RyanaP , MakridesbM . Analysis of binary outcomes from randomised trials including multiple births: When should clustering be taken into account?. Paediatric and Perinatal Epidemiology2011;25:283–97. ">Yelland 2011</a>. For dichotomous outcomes, the numerator and denominator were adjusted and for continuous outcomes the denominator only was adjusted. </p> </section> </section> </section> <section id="CD002255-sec-0089"> <h3 class="title" id="CD002255-sec-0089">Effects of interventions</h3> <p>Comparisons and subgroup analyses were undertaken as follows:</p> <p> <ul id="CD002255-list-0018"> <li> <p>Comparison 1: any CCB compared with placebo or no intervention.</p> </li> <li> <p>Comparison 2: any CCB compared with any other tocolytic agent subgrouped by type of tocolytic: betamimetics, magnesium sulphate, oxytocin receptor antagonists (ORA), non‐steroidal anti‐inflammatory drugs (NSAIDs), glyceryl trinitrate (GTN) patch. </p> </li> <li> <p>Comparison 3: any CCB compared with betamimetics subgrouped by type of CCB: nifedipine, nicardipine. </p> </li> <li> <p>Comparison 4: any CCB compared with magnesium sulphate subgrouped by type of CCB: nifedipine, nicardipine. </p> </li> <li> <p>Comparison 5: higher dose CCBs compared with lower dose CCBs.</p> </li> </ul> </p> <p>We were unable to conduct the planned subgroup analyses to explore the effects at different gestational age thresholds by membrane status and multiple gestation due to the unavailability of data. Comparisons for CCB versus ORA, NSAID, and GTN patch subgrouped by type of CCB were not undertaken due to insufficient data. </p> <section id="CD002255-sec-0090"> <h4 class="title">Comparison 1: CCB compared with placebo or no treatment</h4> <p>Two studies including 173 women are included in this comparison (<a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a>; <a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a>). One trial (<a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a>) randomised women to one of three groups: two different dosages of nifedipine or no treatment. In this comparison we combined the two nifedipine groups. </p> <section id="CD002255-sec-0091"> <h5 class="title">Primary outcomes</h5> <p><b>Birth less than 48 hours after trial entry</b> (<a href="./references#CD002255-fig-0006" title="">Analysis 1.1</a>) </p> <p>Comparing CCB versus placebo or no treatment, a reduction in birth less than 48 hours after trial entry was shown (risk ratio (RR) 0.30, 95% confidence interval (CI) 0.21 to 0.43; number needed to treat for an additional beneficial outcome (NNTB) 2, 95% CI 2 to 3), (two trials with 173 women). </p> <p>No other primary outcomes were reported.</p> </section> <section id="CD002255-sec-0092"> <h5 class="title">Secondary outcomes</h5> <p><b>For the infant/child</b> </p> <p><b>Preterm birth (before completion of 37 weeks of gestation)</b> </p> <p>Two trials (173 women) reported the outcome of preterm birth (before completion of 37 weeks of gestation). Due to substantial heterogeneity (T² = 0.88, Chi² = 53.79, df = 1 (P &lt; 0.001), I² = 98%), these outcome data were not combined (<a href="./references#CD002255-fig-0007" title="">Analysis 1.2</a>). </p> <p>One placebo controlled trial (89 women) (<a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a>) showed no difference in preterm birth (RR 0.96, 95% CI 0.89 to 1.03) while the other (non‐placebo controlled trial) (84 women) (<a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a>) reported a reduction (RR 0.44, 95% CI 0.31 to 0.62; NNTB 2, 95% CI 2 to 3). </p> <p><b>For the woman</b> </p> <p><b>Maternal adverse effects</b> (<a href="./references#CD002255-fig-0008" title="">Analysis 1.3</a>) </p> <p>An increase in maternal adverse effects was shown for CCB compared with placebo or no treatment (one trial; 89 women; RR 49.89, 95% CI 3.13 to 795.02; no events were reported in the control group). </p> <p>No other outcomes were reported.</p> </section> </section> <section id="CD002255-sec-0093"> <h4 class="title">Comparison 2: CCB compared with any other tocolytic agent by type of tocolytic</h4> <p>A total of 35 studies including 3275 women are included in the comparisons of CCB versus other tocolytics as follows: </p> <p> <ul id="CD002255-list-0019"> <li> <p>CCB versus betamimetics: 23 studies with 1793 women.</p> </li> <li> <p>CCB versus magnesium sulphate: seven studies with 943 women.</p> </li> <li> <p>CCB versus NSAID: two studies with 358 women.</p> </li> <li> <p>CCB versus ORA: two studies with 225 women.</p> </li> <li> <p>CCB versus GTN patch: one study with 54 women.</p> </li> </ul> </p> <section id="CD002255-sec-0094"> <h5 class="title">Primary outcomes</h5> <p><b>Birth less than 48 hours after trial entry</b> (<a href="./references#CD002255-fig-0009" title="">Analysis 2.1</a>) </p> <p>A moderate degree of statistically heterogeneity was evident for this outcome measure in the comparisons of CCB versus betamimetics, NSAID and ORA. However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p>While a trend towards fewer women giving birth less than 48 hours after trial entry was evident, this was not statistically significant for any tocolytic comparison groups as follows: </p> <p> <ul id="CD002255-list-0020"> <li> <p>CCB versus betamimetics (19 studies; 1505 women; average RR 0.86, 95% CI 0.67 to 1.10), (T² = 0.09, Chi² = 28.52, df = 18 (P = 0.05), I² = 37%). </p> </li> <li> <p>CCB versus magnesium sulphate (five studies; 651 women; average RR 0.83, 95% CI 0.61 to 1.13). </p> </li> <li> <p>CCB versus NSAID (two studies; 218 women; average RR 0.63, 95% CI 0.29 to 1.41), (T² = 0.23, Chi² = 3.43, df = 1 (P = 0.06), I² = 71%). </p> </li> <li> <p>CCB versus ORA (two studies; 225 women; average RR 0.92, 95% CI 0.37 to 2.30), (T² = 0.22, Chi² = 2.04, df = 1 (P = 0.15), I² = 51%). </p> </li> <li> <p>CCB versus GTN patch (one study; 53 women; average RR 0.91, 95% CI 0.22 to 3.66).</p> </li> </ul> </p> <p>A funnel plot for this analysis (<a href="#CD002255-fig-0003">Figure 3</a>) was reasonably symmetrical, suggesting the absence of important bias or small‐study effects in the set of studies. </p> <p><b>Very preterm birth (before completion of 34 weeks of gestation)</b> (<a href="./references#CD002255-fig-0010" title="">Analysis 2.2</a>) </p> <p>A statistically significant reduction in very preterm birth was shown for:</p> <p> <ul id="CD002255-list-0021"> <li> <p>CCB versus betamimetics (six studies; 630 women; RR 0.78, 95% CI 0.66 to 0.93; NNTB 11, 95% CI 7 to 33). </p> </li> </ul> </p> <p>No differences were shown for other tocolytic comparisons as follows:</p> <p> <ul id="CD002255-list-0022"> <li> <p>CCB versus magnesium sulphate (four studies; 429 women; RR 0.95, 95% CI 0.76 to 1.20).</p> </li> <li> <p>CCB versus ORA (one study; 145 women; RR 0.59, 95% CI 0.31 to 1.12).</p> </li> <li> <p>CCB versus NSAID (one study; 139 women; RR 1.10, 95% CI 0.86 to 1.42).</p> </li> </ul> </p> <p>No data were available for the CCB versus GTN patch comparison.</p> <p><b>Perinatal mortality</b> (<a href="./references#CD002255-fig-0011" title="">Analysis 2.3</a>) </p> <p>No statistically significant differences in perinatal mortality were shown for any of the tocolytic subgroups as follows: </p> <p> <ul id="CD002255-list-0023"> <li> <p>CCB versus betamimetics (17 studies; 1233 babies; RR 0.85, 95% CI 0.52 to 1.38).</p> </li> <li> <p>CCB versus magnesium sulphate (five studies; 657 babies; RR 1.07, 95% CI 0.36 to 3.13).</p> </li> <li> <p>CCB versus NSAID (two studies; 239 babies; RR 0.39, 95% CI 0.10 to 1.51).</p> </li> </ul> </p> <p>No data were available for the other subgroup comparisons.</p> <p>A funnel plot for this analysis (<a href="#CD002255-fig-0004">Figure 4</a>) was reasonably symmetrical, suggesting the absence of important bias or small‐study effects in the set of studies. </p> <p><b>Stillbirth</b> (<a href="./references#CD002255-fig-0012" title="">Analysis 2.4</a>) </p> <p>No statistically significant differences in stillbirth were shown for any of the tocolytic subgroups as follows: </p> <p> <ul id="CD002255-list-0024"> <li> <p>CCB versus betamimetics (13 studies; 934 women; RR 1.03, 95% CI 0.15 to 7.23).</p> </li> <li> <p>CCB versus magnesium sulphate (five studies; 657 women; RR 2.39, 95% CI 0.10 to 57.18).</p> </li> <li> <p>CCB versus NSAID (one study; 160 women; RR not estimable (no stillbirths reported)).</p> </li> </ul> </p> <p>No data were available for the other subgroup comparisons.</p> <p><b>Neonatal death</b> (<a href="./references#CD002255-fig-0013" title="">Analysis 2.5</a>) </p> <p>No statistically significant differences in neonatal death were shown for any of the tocolytic subgroups as follows: </p> <p> <ul id="CD002255-list-0025"> <li> <p>CCB versus betamimetics (15 studies; 1068 babies; RR 0.96, 95% CI 0.53 to 1.75).</p> </li> <li> <p>CCB versus magnesium sulphate (five studies; 657 babies; RR 0.94, 95% CI 0.30 to 3.00).</p> </li> <li> <p>CCB versus ORA (one study; 179 babies; RR not estimable (no neonatal deaths reported)).</p> </li> <li> <p>CCB versus NSAID (two studies; 239 babies; RR 0.39, 95% CI 0.10 to 1.51).</p> </li> </ul> </p> <p>No data were available for the CCB versus GTN patch subgroup comparison.</p> <p><b>Maternal death</b> (<a href="./references#CD002255-fig-0014" title="">Analysis 2.6</a>) </p> <p>There were no maternal deaths reported in one study of 276 women (<a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>, (three‐armed trial) comparing CCB with magnesium sulphate and NSAID (RR not estimable). </p> <p>No data were available for the other tocolytic comparisons.</p> <p>No data were available for other serious maternal outcomes (cardiac arrest, respiratory arrest, admission to intensive care unit). </p> </section> <section id="CD002255-sec-0095"> <h5 class="title">Secondary outcomes</h5> <p><b>For the infant/child</b> </p> <p><b>Interval between trial entry and birth</b> (days) (<a href="./references#CD002255-fig-0015" title="">Analysis 2.7</a>) </p> <p>A moderate degree of statistical heterogeneity was evident for this outcome measure in the comparison of CCB versus betamimetics (T² = 22.52, Chi² = 23.51, df = 9 (P = 0.005), I² = 62%). However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p>A statistically significant increase in the interval between trial entry and birth was shown for: </p> <p> <ul id="CD002255-list-0026"> <li> <p>CCB versus betamimetics (10 studies; 830 women; average mean difference (MD) 4.38 days, 95% CI 0.25 to 8.52). </p> </li> </ul> </p> <p>No differences were shown for the other tocolytic comparisons as follows:</p> <p> <ul id="CD002255-list-0027"> <li> <p>CCB versus magnesium sulphate (two studies; 212 women; average MD ‐1.63, 95% CI ‐8.80 to 5.54). </p> </li> <li> <p>CCB versus ORA (one study; 145 women; average MD 5.70, 95% CI ‐0.96 to 12.36).</p> </li> </ul> </p> <p>No data were available for the other tocolytic comparisons.</p> <p><b>Gestational age at birth (completed weeks)</b> (<a href="./references#CD002255-fig-0016" title="">Analysis 2.8</a>) </p> <p>A statistically significant increase in gestational age at birth was shown for:</p> <p> <ul id="CD002255-list-0028"> <li> <p>CCB versus betamimetics (14 studies; 1063 women; MD 0.71 weeks, 95% CI 0.34 to 1.09); and </p> </li> <li> <p>CCB versus ORA (one study; 145 women; MD 1.20 weeks, 95% CI 0.25 to 2.15).</p> </li> </ul> </p> <p>No differences were shown for other tocolytic comparisons as follows:</p> <p> <ul id="CD002255-list-0029"> <li> <p>CCB versus magnesium sulphate (five studies; 651 women; MD 0.15, 95% CI ‐0.22 to 0.52).</p> </li> <li> <p>CCB versus NSAID (one study; 139 women; MD 0.00, 95% CI ‐1.51 to 1.51).</p> </li> </ul> </p> <p>No data were available for the GTN patch comparison.</p> <p><b>Preterm birth (before completion of 37 weeks of gestation)</b> (<a href="./references#CD002255-fig-0017" title="">Analysis 2.9</a>) </p> <p>A statistically significant reduction in preterm birth was shown for:</p> <p> <ul id="CD002255-list-0030"> <li> <p>CCB versus betamimetics (13 studies; 1111 women; RR 0.89, 95% CI 0.80 to 0.98; NNTB 16, 95% CI 9 to 86); and </p> </li> <li> <p>CCB versus ORA (one study; 145 women; RR 0.64, 95% CI 0.47 to 0.89; NNTB 5, 95% CI 3 to 15). </p> </li> </ul> </p> <p>A funnel plot for this analysis (<a href="#CD002255-fig-0005">Figure 5</a>) was reasonably symmetrical, suggesting the absence of important bias or small‐study effects in the set of studies. </p> <p>No differences were shown for other tocolytic comparisons as follows:</p> <p> <ul id="CD002255-list-0031"> <li> <p>CCB versus magnesium sulphate (four studies; 499 women; (RR 0.92, 95% CI 0.81 to 1.06).</p> </li> <li> <p>CCB versus NSAID (one study; 139 women; (RR 0.91, 95% CI 0.78 to 1.06).</p> </li> </ul> </p> <p>No data were available for the GTN patch comparison.</p> <p><b>Extremely preterm birth (before completion of 28 weeks of gestation)</b> (<a href="./references#CD002255-fig-0018" title="">Analysis 2.10</a>) </p> <p>No statistically significant difference in extremely preterm birth was shown for:</p> <p> <ul id="CD002255-list-0032"> <li> <p>CCB versus ORA (one study; 145 women; RR 0.47, 95% CI 0.04 to 5.03).</p> </li> </ul> </p> <p><b>Apgar score less than seven at five minutes</b> (<a href="./references#CD002255-fig-0019" title="">Analysis 2.11</a>) </p> <p>No statistically significant differences in Apgar score less than seven at five minutes was shown for: </p> <p> <ul id="CD002255-list-0033"> <li> <p>CCB versus betamimetics (six studies; 557 babies; RR 0.53, 95% CI 0.26 to 1.06).</p> </li> <li> <p>CCB versus magnesium sulphate (two studies; 217 babies; RR 1.10, 95% CI 0.48 to 2.51).</p> </li> <li> <p>CCB versus ORA (one study; 179 babies; RR 1.85, 95% CI 0.17 to 20.03).</p> </li> </ul> </p> <p>No data were available for the other tocolytic comparisons.</p> <p><b>Admissions to NICU</b> (<a href="./references#CD002255-fig-0020" title="">Analysis 2.12</a>) </p> <p>A statistically significant reduction in NICU admission shown for:</p> <p> <ul id="CD002255-list-0034"> <li> <p>CCB versus betamimetics (12 studies; 999 babies; average RR 0.74, 95% CI 0.63 to 0.87; NNTB 12, 95% CI 9 to 23). </p> </li> <li> <p>CCB versus ORA (one study; 179 babies; average RR 0.59, 95% CI 0.41 to 0.85; NNTB 5, 95% CI 4 to 14). </p> </li> </ul> </p> <p>No differences were shown for:</p> <p> <ul id="CD002255-list-0035"> <li> <p>CCB versus magnesium sulphate (two studies; 331 babies; average RR 1.00, 95% CI 0.48 to 2.08),(T² = 0.21, Chi² = 3.86, df = 1 (P = 0.05), I² = 74%). </p> </li> </ul> </p> <p>No data were available for the other tocolytic comparisons.</p> <p><b>Respiratory distress syndrome (RDS)</b> (<a href="./references#CD002255-fig-0021" title="">Analysis 2.13</a>) </p> <p>A statistically significant reduction in RDS was shown for:</p> <p> <ul id="CD002255-list-0036"> <li> <p>CCB versus betamimetics (16 studies; 1293 babies; RR 0.64, 95% CI 0.48 to 0.86; NNTB 19, 95% CI 13 to 47). </p> </li> </ul> </p> <p>No differences were shown for other tocolytic comparisons as follows:</p> <p> <ul id="CD002255-list-0037"> <li> <p>CCB versus magnesium sulphate (four studies; 577 babies; RR 0.76, 95% CI 0.56 to 1.05).</p> </li> <li> <p>CCB versus ORA (one study; 179 babies; RR 0.72, 95% CI 0.28 to 1.85).</p> </li> <li> <p>CCB versus NSAID (one study; 160 babies; RR 0.71, 95% CI 0.45 to 1.13).</p> </li> </ul> </p> <p>No data were available for the GTN patch comparison.</p> <p><b>Chronic lung disease</b> (<a href="./references#CD002255-fig-0022" title="">Analysis 2.14</a>) </p> <p>There were no cases of chronic lung disease in one study of 91 babies (<a href="./references#CD002255-bbs2-0036" title="Van DeWaterM , KesselET , DeKleineMJ , OeiSG . Tocolytic effectiveness of nifedipine versus ritodrine and follow‐up of newborns: a randomised controlled trial. Acta Obstetricia et Gynecologica2008;87(3):340‐5. ">Van De Water 2008</a>) comparing CCB with betamimetics (RR not estimable). </p> <p>No data were available for the other tocolytic comparisons.</p> <p><b>Necrotising enterocolitis</b> (NEC) (<a href="./references#CD002255-fig-0023" title="">Analysis 2.15</a>) </p> <p>A statistically significant reduction in NEC was shown for:</p> <p> <ul id="CD002255-list-0038"> <li> <p>CCB versus betamimetics (five studies; 490 babies; RR 0.21, 95% CI 0.05 to 0.96; NNTB 38, 95% CI 32 to 747). </p> </li> </ul> </p> <p>No differences were shown for other tocolytic comparisons as follows:</p> <p> <ul id="CD002255-list-0039"> <li> <p>CCB versus magnesium sulphate (two studies; 360 babies; RR 0.64, 95% CI 0.13 to 3.20).</p> </li> <li> <p>CCB versus ORA (one study; 179 babies; RR 0.10, 95% CI 0.01 to 1.88).</p> </li> <li> <p>CCB versus NSAID (one study; 160 babies; RR 0.68, 95% CI 0.14 to 3.42).</p> </li> </ul> </p> <p>No data were available for the CCB versus GTN patch other tocolytic comparison.</p> <p><b>Neonatal sepsis</b> (<a href="./references#CD002255-fig-0024" title="">Analysis 2.16</a>) </p> <p>No statistically significant differences in neonatal sepsis was shown for the following:</p> <p> <ul id="CD002255-list-0040"> <li> <p>CCB versus betamimetics (seven studies; 618 babies; RR 0.72, 95% CI 0.47 to 1.11).</p> </li> <li> <p>CCB versus magnesium sulphate (two studies; 360 babies; RR 0.71, 95% CI 0.31 to 1.63).</p> </li> <li> <p>CCB versus ORA (one study; 179 babies; RR 1.39, 95% CI 0.24 to 8.10).</p> </li> <li> <p>CCB versus NSAID (one study; 160 babies; RR 0.66, 95% CI 0.25 to 1.75).</p> </li> </ul> </p> <p>No data were available for the comparison of CCB versus GTN patch.</p> <p><b>Neonatal jaundice</b> (<a href="./references#CD002255-fig-0025" title="">Analysis 2.17</a>) </p> <p>A statistically significant reduction in neonatal jaundice was shown for:</p> <p> <ul id="CD002255-list-0041"> <li> <p>CCB versus betamimetics (three studies; 334 babies; RR 0.72, 95% CI 0.57 to 0.92; NNTB 9, 95% CI 6 to 31). </p> </li> </ul> </p> <p>No data were available for the other tocolytic comparisons.</p> <p><b>Intraventricular haemorrhage (IVH)</b> (<a href="./references#CD002255-fig-0026" title="">Analysis 2.18</a>) </p> <p>A statistically significant reduction in IVH was shown for:</p> <p> <ul id="CD002255-list-0042"> <li> <p>CCB versus betamimetics (seven studies; 596 babies; RR 0.53, 95% CI 0.34 to 0.84; NNTB 15, 95% CI 11 to 44). </p> </li> </ul> </p> <p>No differences were shown for other subgroups as follows:</p> <p> <ul id="CD002255-list-0043"> <li> <p>CCB versus magnesium sulphate (two studies; 360 babies; RR 0.71, 95% CI 0.30 to 1.69).</p> </li> <li> <p>CCB versus ORA (one study; 179 babies; RR 0.46, 95% CI 0.09 to 2.46).</p> </li> <li> <p>CCB versus NSAID (one study; 160 babies; RR 0.61, 95% CI 0.23 to 1.61).</p> </li> </ul> </p> <p>No data were available for the CCB versus GTN patch comparison.</p> <p><b>Grades three or four IVH</b> (<a href="./references#CD002255-fig-0027" title="">Analysis 2.19</a>) </p> <p>No statistically significant difference was shown in grades three or four IVH for:</p> <p> <ul id="CD002255-list-0044"> <li> <p>CCB versus betamimetics (six studies; 560 babies; RR 0.63, 95% CI 0.23 to 1.74).</p> </li> </ul> </p> <p>No data were available for the other tocolytic comparisons.</p> <p><b>Periventricular leukomalacia (PVL)</b> (<a href="./references#CD002255-fig-0028" title="">Analysis 2.20</a>) </p> <p>No statistically significant difference in PVL was shown in the single study reporting this outcome (<a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>) as follows: </p> <p> <ul id="CD002255-list-0045"> <li> <p>CCB versus magnesium sulphate (one study; 151 babies; no events reported).</p> </li> <li> <p>CCB versus NSAID (one study; 160 babies; RR 0.34, 95% CI 0.02 to 6.96).</p> </li> </ul> </p> <p>No data were available for the other subgroup comparisons.</p> <p><b>Retinopathy of prematurity</b> (ROP) (<a href="./references#CD002255-fig-0029" title="">Analysis 2.21</a>) </p> <p>No statistically significant differences in ROP was shown for:</p> <p> <ul id="CD002255-list-0046"> <li> <p>CCB versus betamimetics (two studies; 276 babies; RR 0.15, 95% CI 0.02 to 1.28).</p> </li> <li> <p>CCB versus ORA (one study; 179 babies; RR 0.46, 95% CI 0.04 to 5.01).</p> </li> </ul> </p> <p>No data were available for the other tocolytic comparisons.</p> <p><b>For the woman</b> </p> <p><b>Maternal adverse effects</b> (<a href="./references#CD002255-fig-0030" title="">Analysis 2.22</a>) </p> <p>Statistical heterogeneity was evident within the CCB versus betamimetic comparison. However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies within this comparison, we considered an overall summary was meaningful using a random‐effects analysis. Differences were evident across these comparisons: Test for subgroup differences: Chi² = 39.20, df = 4 (P &lt;0.01) I² = 89.9%. </p> <p>Statistically significant fewer maternal adverse effects were shown for CCB when compared to betamimetics and magnesium sulphate: </p> <p> <ul id="CD002255-list-0047"> <li> <p>CCB versus betamimetics (15 studies; 1305 women; average RR 0.36, 95% CI 0.24 to 0.53; NNTB 4, 95% CI 3), (T² = 0.36, Chi² = 62.40, df = 14 (P &lt; 0.01), I² = 78%). </p> </li> <li> <p>CCB versus magnesium sulphate (five studies; 604 women; average RR 0.52, 95% CI 0.40 to 0.68; NNTB 7, 95% CI 6 to 10). </p> </li> </ul> </p> <p>CCB resulted in statistically significant more maternal adverse effects when compared with ORA: </p> <p> <ul id="CD002255-list-0048"> <li> <p>CCB versus ORA (two studies; 225 women; average RR 2.61, 95% CI 1.43 to 4.74; number needed to treat for an additional harmful outcome (NNTH) 6, 95% CI 3 to 22). </p> </li> </ul> </p> <p>No differences were shown for the comparisons of CCB versus NSAID or GTN patches as follows: </p> <p> <ul id="CD002255-list-0049"> <li> <p>CCB versus NSAID (one study; 79 women; average RR 1.51, 95% CI 0.81 to 2.79).</p> </li> <li> <p>CCB versus GTN patch (one study; 50 women; average RR 0.60, 95% CI 0.23 to 1.54).</p> </li> </ul> </p> <p><b>Discontinuation of therapy for maternal adverse effects</b> (<a href="./references#CD002255-fig-0031" title="">Analysis 2.23</a>) </p> <p>Statistical heterogeneity was evident for the CCB versus magnesium sulphate comparison. However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies within this comparison, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p>CCB resulted in statistically significant less maternal adverse effects requiring discontinuation of therapy when compared to betamimetic: </p> <p> <ul id="CD002255-list-0050"> <li> <p>CCB versus betamimetics (16 studies; 1217 women; average RR 0.22, 95% CI 0.10 to 0.48; NNTB 15, 95% CI 13 to 23). </p> </li> </ul> </p> <p>No differences were shown for other tocolytic comparisons as follows:</p> <p> <ul id="CD002255-list-0051"> <li> <p>CCB versus magnesium sulphate (three studies; 339 women; average RR 1.61, 95% CI 0.10 to 25.91). Test for statistical heterogeneity: T² = 3.68, Chi² = 5.14, df = 2 (P = 0.08), I² = 61%. </p> </li> <li> <p>CCB versus ORA (one study; 145 women; average RR 2.80, 95% CI 0.12 to 67.68).</p> </li> <li> <p>CCB versus NSAID (one study; 139 women; average RR 0.84, 95% CI 0.22 to 3.20).</p> </li> </ul> </p> <p>No data were available for the CCB versus GTN patch tocolytic comparison.</p> <p><b>Caesarean section</b> (<a href="./references#CD002255-fig-0032" title="">Analysis 2.24</a>). </p> <p>No statistically significant differences in caesarean section was shown for:</p> <p> <ul id="CD002255-list-0052"> <li> <p>CCB versus betamimetics (one study; 107 women; RR 0.72, 95% CI 0.38 to 1.38).</p> </li> <li> <p>CCB versus ORA (one study; 145 women; RR 0.75, 95% CI 0.21 to 2.67).</p> </li> </ul> </p> <p>No data were available for the other tocolytic comparison.</p> <p>No other maternal outcomes were reported.</p> <p><b>Long‐term outcomes</b> </p> <p> <ul id="CD002255-list-0053"> <li> <p>CCB (nifedipine) versus betamimetics.</p> </li> </ul> </p> <p>Child outcomes at nine to 12 years of age, collected by survey, were included from one study (<a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>) (reported by <a href="./references#CD002255-bbs2-0090" title="HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an International Journal of Obstetrics and Gynaecology2005;113:324‐31. ">Houtzager 2005</a>). Of survivors, 48 of 88 (55%) originally randomised to the nifedipine group responded to the survey compared with 54 of 83 (65%) originally randomised to the ritodrine group were included. </p> <p>No difference was shown in: parent report of the child's behavioural problems score (MD ‐2.00, 95% CI ‐6.42 to 2.42) (<a href="./references#CD002255-fig-0035" title="">Analysis 2.27</a>); motor quality score (MD ‐4.30, 95% CI ‐9.96 to 1.36) (<a href="./references#CD002255-fig-0037" title="">Analysis 2.29</a>); need for special education (RR 0.82, 95% CI 0.19 to 3.45) (<a href="./references#CD002255-fig-0036" title="">Analysis 2.28</a>); or child report of quality of life measures for any of the six domains (Physical, Motor, Autonomy, Cognitive, Social, Poisitve emotion, Negative emotion) <a href="./references#CD002255-fig-0038" title="">Analysis 2.30</a>. </p> <p>No difference was shown in parent distress scores (for the woman) (MD ‐1.00, 95% CI ‐9.25 to 7.25) (<a href="./references#CD002255-fig-0045" title="">Analysis 2.37</a>). </p> <p>No data were available for other tocolytic comparison.</p> <section id="CD002255-sec-0096"> <h6 class="title">Health service utilisation</h6> <p><b>Duration of stay in NICU (days)</b> (<a href="./references#CD002255-fig-0033" title="">Analysis 2.25</a>) </p> <p>A reduction in the length of NICU stay was shown for:</p> <p> <ul id="CD002255-list-0054"> <li> <p>CCB versus magnesium sulphate (two studies; 360 babies; MD ‐4.55, 95% CI ‐8.17 to ‐0.92). </p> </li> <li> <p>CCB versus ORA. (one study; 179 babies; MD ‐5.40, 95% CI ‐10.84 to 0.04).</p> </li> </ul> </p> <p>No difference was shown for:</p> <p> <ul id="CD002255-list-0055"> <li> <p>CCB versus NSAID (one study; 160 women; MD 3.60, 95% CI ‐8.27 to 15.47).</p> </li> </ul> </p> <p>No data were available for the other tocolytic comparison.</p> <p><b>Duration of stay in maternal hospital (days)</b> (<a href="./references#CD002255-fig-0034" title="">Analysis 2.26</a>) </p> <p> <ul id="CD002255-list-0056"> <li> <p>CCB versus betamimetics. No difference was shown in the duration of maternal hospital stay (one trial, 52 women) (MD 0.18 days, 95% CI ‐1.04 to 1.40). </p> </li> </ul> </p> <p>No data were available for the other tocolytic comparison.</p> </section> </section> </section> <section id="CD002255-sec-0097"> <h4 class="title">Comparison 3: CCB compared with betamimetics (subgrouped by type of CCB)</h4> <p>A total of 23 studies with 1793 women are included in the comparison of CCB versus betamimetics subgrouped by type; three studies used nicardipine (<a href="./references#CD002255-bbs2-0015" title="JannetD , AbankwaA , GuyardB , CarbonneB , MarpeauL , MilliezJ . Nicardipine versus salbutamol in the treatment of premature labor. A prospective randomized study. European Journal of Obstetrics, Gynecology and Reproductive Biology1997;73(1):11‐6. ">Jannet 1997</a>; <a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>; <a href="./references#CD002255-bbs2-0034" title="TrabelsiK , Hadj TaibH , AmouriH , AbdennadheurW , Ben AmarH , KallelW , et al. Nicardipine versus salbutamol in the treatment of premature labor: comparison of their efficacy and side effects. Tunisie Medicale2008;86(1):43‐8. ">Trabelsi 2008</a>) and the remainder used nifedipine. No differences were evident by type of tocolytic for any included outcomes measures. </p> <section id="CD002255-sec-0098"> <h5 class="title">Primary outcomes</h5> <p><b>Birth less than 48 hours after trial entry</b> (<a href="./references#CD002255-fig-0046" title="">Analysis 3.1</a>) </p> <p>Statistical heterogeneity was evident for the CCB versus betamimetics comparison. However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies within this comparison, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p> <ul id="CD002255-list-0057"> <li> <p>Nifedipine versus betamimetics. No statistically significant difference in number of women giving birth less than 48 hours after trial entry was shown: (19 studies; 1505 women; average RR 0.86, 95% CI 0.67 to 1.10) (T² = 0.09, Chi² = 28.52, df = 18 (P = 0.05), I² = 37%). </p> </li> <li> <p>Nicardipine versus betamimetics. No data were available.</p> </li> </ul> </p> <p><b>Very preterm birth (before completion of 34 weeks of gestation)</b> (<a href="./references#CD002255-fig-0047" title="">Analysis 3.2</a>) </p> <p> <ul id="CD002255-list-0058"> <li> <p>Nifedipine versus betamimetics. A significant reduction in very preterm birth was shown (five studies; 544 women; RR 0.78, 95% CI 0.66 to 0.93; NNTB 10, 95% CI 6 to 29). </p> </li> <li> <p>Nicardipine versus betamimetics. No difference was shown (one study; 86 women; RR 0.50, 95% CI 0.05 to 5.31). </p> </li> </ul> </p> <p><b>Perinatal mortality</b> (<a href="./references#CD002255-fig-0048" title="">Analysis 3.3</a>) </p> <p>No statistically significant differences in perinatal mortality were shown as follows:</p> <p> <ul id="CD002255-list-0059"> <li> <p>Nifedipine versus betamimetics (16 studies; 1188 babies; RR 0.88, 95%, CI 0.53 to 1.44). </p> </li> <li> <p>Nicardipine versus betamimetics (one study; 45 babies; RR 0.29, 95% CI 0.01 to 6.84).</p> </li> </ul> </p> <p>No data were available for other primary outcome measures.</p> </section> <section id="CD002255-sec-0099"> <h5 class="title">Secondary outcomes</h5> <p><b>For the infant/child</b> </p> <p><b>Interval between trial entry and birth (days)</b> (<a href="./references#CD002255-fig-0049" title="">Analysis 3.4</a>) </p> <p>Statistical heterogeneity was evident for the CCB versus betamimetics comparison. However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies within this comparison, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p>A statistically significant increase in interval between trial entry and birth was shown for: </p> <p> <ul id="CD002255-list-0060"> <li> <p>Nifedipine versus betamimetics. An increase in interval between trial entry and birth was shown (10 studies; 830 women; average MD (days) 4.38, 95% CI 0.25 to 8.52), (T² = 22.52, Chi² = 23.51, df = 9 (P = 0.005), I² = 62%). </p> </li> <li> <p>Nicardipine versus betamimetics. No data were available.</p> </li> </ul> </p> <p><b>Respiratory distress syndrome (RDS)</b> (<a href="./references#CD002255-fig-0050" title="">Analysis 3.5</a>) </p> <p>Nifedipine versus betamimetics. A statistically significant reduction in RDS was shown (16 studies; 1293 babies; RR 0.64, 95% CI 0.48 to 0.86; NNTB 19, 95% CI 13 to 47). </p> <p> <ul id="CD002255-list-0061"> <li> <p>Nicardipine versus betamimetics. No data were available.</p> </li> </ul> </p> <p><b>For the woman</b> </p> <p><b>Discontinuation of therapy for maternal adverse effects</b> (<a href="./references#CD002255-fig-0051" title="">Analysis 3.6</a>) </p> <p> <ul id="CD002255-list-0062"> <li> <p>Nifedipine versus betamimetics. Statistically significantly fewer women required discontinuation of therapy for maternal adverse effects with the use of nifedipine ((15 studies; 1172 women, RR 0.21, 95% CI 0.11 to 0.40; NNTB 17, 95% CI 15 to 22). </p> </li> <li> <p>Nicardipine versus betamimetics. A marginally non‐significant reduction was shown (1 study; 45 women; RR 0.07, 95% CI 0.00 to 1.13). </p> </li> </ul> </p> </section> </section> <section id="CD002255-sec-0100"> <h4 class="title">Comparison 4: CCB compared with magnesium sulphate (subgrouped by type of CCB)</h4> <p>Seven studies with 943 women are included in the comparison of magnesium sulphate subgrouped by type of CCB; one study used nicardipine (<a href="./references#CD002255-bbs2-0024" title="LarmonJ , RossB , MayW , DickersonG , FischerR , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. RossE , RossB , DickersonG , FischerR , MorrisonJ . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1998;178(1):181. ">Larmon 1999</a>) and the remainder used nifedipine. </p> <section id="CD002255-sec-0101"> <h5 class="title">Primary outcomes</h5> <p><b>Birth less than 48 hours after trial entry</b> (<a href="./references#CD002255-fig-0052" title="">Analysis 4.1</a>) </p> <p>No statistically significant differences in number of women giving birth prior to 48 hours were shown: </p> <p> <ul id="CD002255-list-0063"> <li> <p>Nifedipine versus magnesium sulphate (four studies; 529 women; RR 0.83, 95% CI 0.60 to 1.14). </p> </li> <li> <p>Nicardipine versus magnesium sulphate (one study; 122 women; RR 1.14, 95% CI 0.30 to 4.35). </p> </li> </ul> </p> <p><b>Very preterm birth (before completion of 34 weeks of gestation)</b> (<a href="./references#CD002255-fig-0053" title="">Analysis 4.2</a>) </p> <p>No statistically significant differences in very preterm birth were shown:</p> <p> <ul id="CD002255-list-0064"> <li> <p>Nifedipine versus magnesium sulphate (three studies; 307 women; RR 0.98, 95% CI 0.78 to 1.23). </p> </li> <li> <p>Nicardipine versus magnesium sulphate (one study; 122 women; RR 0.71, 95% CI 0.25 to 2.06). </p> </li> </ul> </p> <p><b>Perinatal mortality</b> (<a href="./references#CD002255-fig-0054" title="">Analysis 4.3</a>) </p> <p>No statistically significant difference in perinatal mortality were shown:</p> <p> <ul id="CD002255-list-0065"> <li> <p>Nifedipine versus magnesium sulphate (four studies; 535 babies; RR 1.07, 95% CI 0.36 to 3.13). </p> </li> <li> <p>Nicardipine versus magnesium sulphate. (one study; 122 babies); no cases of perinatal mortality were reported. </p> </li> </ul> </p> <p><b>Maternal death</b> (<a href="./references#CD002255-fig-0055" title="">Analysis 4.4</a>) </p> <p>There were no cases of maternal deaths reported in one study of 276 women (<a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>, three‐armed trial) comparing nifedipine with magnesium sulphate (RR not estimable). </p> <p>No data were available for the nicardipine subgroup comparison.</p> </section> <section id="CD002255-sec-0102"> <h5 class="title">Secondary outcomes</h5> <p><b>For the infant/child</b> </p> <p><b>Interval between trial entry and birth</b> (<a href="./references#CD002255-fig-0056" title="">Analysis 4.5</a>) </p> <p>No statistically significant differences in interval between trial entry and birth were shown for: </p> <p> <ul id="CD002255-list-0066"> <li> <p>Nifedipine versus magnesium sulphate (one study; 90 women; MD ‐5.80, 95% CI ‐18.59 to 6.99). </p> </li> <li> <p>Nicardipine versus magnesium sulphate (one study; 122 women; MD 0.28, 95% CI ‐8.37 to 8.93). </p> </li> </ul> </p> <p><b>Respiratory distress syndrome (RDS)</b> (<a href="./references#CD002255-fig-0057" title="">Analysis 4.6</a>) </p> <p>No statistically significant differences in RDS was shown for:</p> <p> <ul id="CD002255-list-0067"> <li> <p>Nifedipine versus magnesium sulphate (three studies; 455 babies; RR 0.78, 95% CI 0.56 to 1.09). </p> </li> <li> <p>Nicardipine versus magnesium sulphate (one study; 122 babies; RR 0.63, 95% CI 0.23 to 1.78). </p> </li> </ul> </p> <p><b>For the woman</b> </p> <p><b>Discontinuation of therapy for maternal adverse effects</b> (<a href="./references#CD002255-fig-0058" title="">Analysis 4.7</a>) </p> <p>Statistical heterogeneity was evident for the CCB versus magnesium sulphate comparison. However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies within this comparison, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p>No differences were shown in the need for discontinuation of therapy for maternal adverse effects for: </p> <p> <ul id="CD002255-list-0068"> <li> <p>Nifedipine versus magnesium sulphate (two studies; 217 women; average RR 1.14, 95% CI 0.01 to 101.65, random‐effects), (T² = 8.28, Chi² = 4.74, df = 1 (P = 0.03), I² = 79%). </p> </li> <li> <p>Nicardipine versus magnesium sulphate (one study; 122 women; average RR 3.41, 95% CI 0.14 to 82.18). </p> </li> </ul> </p> </section> </section> <section id="CD002255-sec-0103"> <h4 class="title">Comparison 5: Higher versus lower dosage of CCB</h4> <p>One study of 102 women (<a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>) compared a higher dose with a lower dose of oral nifedipine and comprehensive unpublished outcome data provided by the authors were included in the review. </p> <section id="CD002255-sec-0104"> <h5 class="title">Primary outcomes</h5> <p><b>Birth within 48 hrs after trial entry</b> (<a href="./references#CD002255-fig-0059" title="">Analysis 5.1</a>). </p> <p>No difference was shown in the outcomes of birth within 48 hours after trial entry (RR 0.77, 95% CI 0.26 to 2.27). </p> <p><b>Perinatal mortality</b> (<a href="./references#CD002255-fig-0062" title="">Analysis 5.4</a>)<b>, Stillbirth</b> (<a href="./references#CD002255-fig-0063" title="">Analysis 5.5</a>) <b>and Neonatal death</b> (<a href="./references#CD002255-fig-0064" title="">Analysis 5.6</a>) </p> <p>No difference was shown in perinatal mortality (RR 0.15, 95% CI 0.01 to 2.92), stillbirth (RR 0.36, 95% CI 0.02 to 8.64), or neonatal death (RR 0.15, 95% CI 0.01 to 2.92). </p> <p><b>Very preterm birth (before completion of 34 weeks of gestation)</b> (<a href="./references#CD002255-fig-0060" title="">Analysis 5.2</a>) </p> <p>No difference was shown in very preterm birth (before completion of 34 weeks of gestation) (RR 0.60, 95% CI 0.31 to 1.17). </p> <p><b>Maternal death</b> (<a href="./references#CD002255-fig-0065" title="">Analysis 5.7</a>) </p> <p>No maternal deaths were reported during the trial period.</p> <p>No data were available for any of the other primary outcome measures.</p> </section> <section id="CD002255-sec-0105"> <h5 class="title">Secondary outcomes</h5> <p><b>For the infant/child</b> </p> <p><b>Interval between trial entry and birth (days)</b> (<a href="./references#CD002255-fig-0066" title="">Analysis 5.8</a>) </p> <p>No difference was shown in the interval between trial entry and birth (MD 7.30 weeks, 95% CI ‐2.21 to 16.81). </p> <p><b>Gestational age at birth (completed weeks)</b> (<a href="./references#CD002255-fig-0067" title="">Analysis 5.9</a>) </p> <p>The mean gestational age at birth was marginally statistically significantly higher for babies of women receiving high‐dose nifedipine (completed weeks) (MD 1.30 weeks, 95% CI 0.03 to 2.57). </p> <p><b>Preterm birth (before 37 weeks' gestation)</b> (<a href="./references#CD002255-fig-0068" title="">Analysis 5.10</a>) </p> <p>No difference was shown in preterm birth (RR 0.83, 95% CI 0.63 to 1.10).</p> <p>No statistically significant differences were shown for the secondary measures of neonatal morbidity and effect estimates are imprecise due to small numbers; the findings tended to favour the high‐dose group as follows: </p> <p><b>Apgar score less than seven at five minutes</b> (RR 0.09, 95% CI 0.01 to 1.53) (<a href="./references#CD002255-fig-0069" title="">Analysis 5.11</a>). </p> <p><b>Admission to the NICU</b> (RR 0.57, 95% CI 0.31 to 1.05) (<a href="./references#CD002255-fig-0070" title="">Analysis 5.12</a>). </p> <p><b>Respiratory distress syndrome (RDS)</b> (RR 0.65, 95% CI 0.26 to 1.65) (<a href="./references#CD002255-fig-0071" title="">Analysis 5.13</a>). </p> <p><b>Necrotising enterocolitis (NEC)</b> (RR 0.22, 95% CI 0.01 to 4.39) (<a href="./references#CD002255-fig-0072" title="">Analysis 5.14</a>). </p> <p><b>Neonatal sepsis</b> (RR 1.08, 95% CI 0.23 to 5.11) (<a href="./references#CD002255-fig-0073" title="">Analysis 5.15</a>). </p> <p><b>Neonatal jaundice</b> (RR 0.57, 95% CI 0.31 to 1.05) (<a href="./references#CD002255-fig-0074" title="">Analysis 5.16</a>). </p> <p><b>Intraventicular haemorrhage</b> (IVH) (RR 0.12, 95% CI 0.01 to 2.18) (<a href="./references#CD002255-fig-0075" title="">Analysis 5.17</a>). </p> <p><b>For the woman</b> </p> <p>No statistically significant differences were shown for maternal adverse effects as follows: </p> <p><b>Maternal adverse effects</b> (RR 1.08, 95% CI 0.33 to 3.51) (<a href="./references#CD002255-fig-0076" title="">Analysis 5.18</a>). </p> <p><b>Discontinuation for maternal adverse effects</b> (RR 5.40, 95% CI 0.27 to 109.76) (<a href="./references#CD002255-fig-0077" title="">Analysis 5.19</a>). </p> <p><b>Health service utilisation</b> </p> <p><b>Duration of stay in NICU (days)</b> (<a href="./references#CD002255-fig-0078" title="">Analysis 5.20</a>) </p> <p>A reduction was shown in the duration of NICU stay with the use of higher dose nifedipine (MD days, ‐4.80 95% CI ‐8.73 to ‐0.87). </p> <p><b>Duration of maternal hospital stay (days)</b> (<a href="./references#CD002255-fig-0079" title="">Analysis 5.21</a>) </p> <p>No difference was shown in maternal length of hospital stay (MD 0.90, 95% CI ‐1.59 to 3.39). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002255-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002255-sec-0106"></div> <section id="CD002255-sec-0107"> <h3 class="title" id="CD002255-sec-0107">Summary of main results</h3> <p>This review update includes 38 included trials involving 3550 women. Of these 38 trials, all but three used nifedipine as the CCB. The remaining three trials (261 women) used nicardipine as the CCB, and no differences in outcomes were shown in trials comparing nicardipine to other tocolytics, although with limited data no strong conclusions can be drawn. It must be noted that the majority of trials did not use blinding of the intervention or outcome assessment. </p> <p>Two small studies with 173 women, (one used a placebo control and the other did not) (<a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a>; <a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a>) comparing CCB with placebo or no treatment were included showing a reduction in birth less than 48 hours after trial entry NNTB 2, 95% CI 2 to 3). The <a href="./references#CD002255-bbs2-0038" title="ZhangX , LiuM . Clinical observations on the prevention and treatment of premature labor with nifedipine. Hua‐Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences]2002;33(2):288‐90. ">Zhang 2002</a> trial of CCB versus no treatment showed a significant reduction in preterm birth, while the placebo controlled <a href="./references#CD002255-bbs2-0003" title="AraI , BanuH . A prospective randomised trial of nifedipine versus placebo in preterm labour. Bangladesh Journal of Obstetrics and Gynecology2008;23(2):61‐4. ">Ara 2008</a> trial showed no difference. Maternal side effects from nifedipine were reported (percentage of women receiving nifedipine versus percentage receiving placebo); however, none were severe (flushing, headache and vertigo). Unfortunately, small numbers do not allow firm conclusions to be made. </p> <p>Comparing CCB (mainly nifedipine) with other tocolytics by type (including betamimetics, glyceryl trinitrate (GTN), non‐steriodal anti inflammatories (NSAID), magnesium sulphate and oxytocin receptor antagonist (ORA)), no significant reductions were shown in the primary outcome measures of birth within 48 hours of treatment or perinatal mortality. </p> <p>In 23 studies of 1793 women, CCB was shown to prolong pregnancy by an average of four days and reduce preterm birth, very preterm birth, and important neonatal morbidity. Long‐term data were limited, although in one study no difference in the child's behavioural/emotional outcome, motor quality, need for special education, quality of life or parent stress (for the woman). Comparing CCB with ORA one study (145 women) showed a significant increase in gestational age at birth (average of one week) and a significant reduction in preterm birth with NNTB on average 5 (95% CI 3 to 15). Comparing CCB with magnesium sulphate (five studies; 651 women) neonatal duration of stay in the NICU was reduced by an average of around five days. No differences were shown in the comparisons with GTN, NSAID although numbers were small. </p> <p>CCB resulted in fewer maternal adverse drug side reactions when compared to betamimetics, but more maternal adverse drug side reactions when compared to ORA and to placebo or no treatment. While cost‐effectiveness data were not available, reductions in NICU admission provides further support for the use of CCB over betamimetics or ORA, and reduced NICU stay (on average four days less) for CCB over magnesium sulphate and ORA. </p> <p>No differences were evident in one small study (102 women), which compared higher‐ versus lower‐dose nifedipine, though findings tended to favour a high dose on some measures of neonatal morbidity (<a href="./references#CD002255-bbs2-0027" title="NassarA , KhalilA , AwwadJ , Abu MusaA , TabbaraJ , UstaI . A randomized trial of two dose regimens of nifedipine for management of preterm labor. American Journal of Obstetrics and Gynecology2007;197(6 Suppl 1):S206. NassarAH , Abu‐MusaAA , AwwadJ , KhaliiA , TabbaraJ , UstaIM . Two dose regimens of nifedipine for management of preterm labor: a randomized controlled trial. American Journal of Perinatology2009;26(8):575‐81. ">Nassar 2009</a>). One of the largest trials in this analysis (<a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>), which had the most favourable outcomes, compared betamimetics with a higher‐dosage regimen for nifedipine than that used in most of the other trials (up to 40 mg in the first hour). However, based on the results of this review, it is not possible to draw any conclusions about optimal nifedipine dosage. </p> </section> <section id="CD002255-sec-0108"> <h3 class="title" id="CD002255-sec-0108">Overall completeness and applicability of evidence</h3> <p>The benefit in terms of postponement of birth and less short‐term neonatal morbidity supports the use of CCB over other tocolytics. However, it must be noted that with the lack of blinding of the intervention and outcome assessment in all trials included in this analysis, the possibility of important bias cannot be ruled out. This is of particularly importance for the less objective outcomes such as measures of neonatal morbidity. Further, these positive effects did not confer benefit in terms of reducing perinatal deaths and the effects on longer‐term outcomes of death and neurosensory impairment are unclear. While robust measures of neurodevelopmental outcome were not available, data collected by survey of women enrolled in one trial (<a href="./references#CD002255-bbs2-0029" title="HoutzagerBA , HogendoornS , SamsonJF , PapatsonisD , VanWassenaerAG . Nine years' follow up of children born from mothers who participated in a RCT of nifedipine versus ritodrine for threatened preterm labor [abstract]. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, USA. 2005:Abstract no: 2100. HoutzagerBA , HogendoornSM , PapatsonisDNM , SamsomJF , vanGeijnHP , BlekerOP , et al. Long‐term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG: an international journal of obstetrics and gynecology2005;113:324‐31. PapatsonisDM , HogendoornSM , HoutzagerBA , vanWassenaerAG , SamsomJF . Long‐term follow‐up of children exposed in utero to nifedipine or ritodrine in the management of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2004; Vol. 191, issue 6 Suppl 1:S106. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and Gynecology2000;95(4):477‐81. PapatsonisDN , KokJH , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Neonatal effects of nifedipine and ritodrine in the management of preterm labor. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:100. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstetrics and Gynecology1997;90(2):230‐4. PapatsonisDN , vanGeijnHP , AderHJ , LangeFM , BlekerOP , DekkerGA . Tocolytic efficacy of nifedipine versus ritodrine; results of a randomized trial. American Journal of Obstetrics and Gynecology1996;174:306. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. International Journal of Gynecology &amp; Obstetrics2003;82(1):5‐10. PapatsonisDN , vanGeijnHP , BlekerOP , AderHJ , DekkerGA . Maternal admission characteristics as risk factors for preterm birth. European Journal of Obstetrics &amp; Gynaecology and Reproductive Biology2004;112:43‐8. PapatsonisDNM , KokJH , SamsomJF , LangeFM , AderHJ , DekkerGA . Neonatal morbidity after randomised trial comparing nifedipine with ritodrine in the management of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1):S117. PapatsonisDNM , vanGeijnHP , DekkerGA . Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor (letter). American Journal of Obstetrics and Gynecology2000;183:513. PapatsonisDNM , vanGeijnHP , KokJH , AderHJ , DekkerGA . Adjuvant use of indomethacin for preterm labor: is it safe to use?. Proceedings of the 5th Annual Congress of the Perinatal Society of Australia and New Zealand; 2001 March; Canberra, Australia. 2001:296. ">Papatsonis 1997</a>) and their children at nine to 12 years of age showed no difference between nifedipine and ritodrine in terms of quality of life and measures of behaviour/emotion, educational and motor quality reported by parents. No data were available on longer‐term outcomes for children of women randomised to tocolytics versus placebo. </p> <p>Of the 38 included trials, all but three used nifedipine as the CCB. The remaining three trials (261 women) used nicardipine as the CCB, and no differences in outcomes were shown in trials comparing nicardipine with other tocolytics, although with limited data no strong conclusions can be drawn. Most of the experience with clinical use of nicardipine is by the intravenous (IV) route. Several cases of pulmonary oedema have been reported in the last 10 years (<a href="./references#CD002255-bbs2-0073" title="AkermanG , MignonA , TsatsarisV , JacqminS , CabrolD , GoffinetF . Pulmonary edema during calcium‐channel blockers therapy: role of predisposing or pharmacologic factors?. Journal of Obstetrics, Gynecology, and Reproductive Biology (Paris)2007;36(4):389‐92. ">Akerman 2007</a>; <a href="./references#CD002255-bbs2-0103" title="PerbetS , ConstantinJM , BolandardF , VignaudM , GallotD , ChanséaumeS , et al. Non‐invasive ventilation for pulmonary edema associated with tocolytic agents during labour for a twin pregnancy. Canadian Journal of Anaesthesia2008;55:769‐73. ">Perbet 2008</a>; <a href="./references#CD002255-bbs2-0106" title="PhilippeHJ , LeTrongA , PigeauH , DemeureD , DesjarsP , EsbelinJ , et al. Acute pulmonary edema occurred during tocolytic treatment using nicardipine in a twin pregnancy: Report of three cases. Journal of Obstetrics, Gynecology, and Reproductive Biology (Paris)2009;38:89‐93. ">Philippe 2009</a>). Although risk factors were present in most of these reports (multiple pregnancy, concomitant use of corticosteroids and/or of betamimetics, cardiovascular history), all of these cases occurred under IV treatment and one of the main factors associated with pulmonary oedema was the high volume of IV fluids perfused. Clinical use of IV nicardipine should cautiously take into account all possible risk factors for pulmonary oedema and the lack of evidence in favour of IV treatment. </p> <p>Comparing CCB with magnesium sulphate, some benefit was shown in terms of reducing neonatal duration of stay in the NICU. No differences were shown in the comparisons with glyceryl trinitrate (GTN), non‐steriodal anti inflammatories (NSAID) although numbers were small. </p> <p>Oxytocin receptor antagonists (ORA) have recently been proposed as a safe and effective tocolytic agent. This review includes two small trials (total of 225 women) comparing CCB (nifedipine) with the ORA atosiban (<a href="./references#CD002255-bbs2-0018" title="KashanianM , BahasadriS , ZolaliB . Comparison of the efficacy and adverse effects of nifedipine and indomethacin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2011;113(3):192‐5. ">Kashanian 2011</a>; <a href="./references#CD002255-bbs2-0032" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 9 April 2008)2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>). Due to small numbers, no conclusions could be drawn on the superiority of one agent over the other. The results of two ongoing trials of atosiban and nifedipine (<a href="./references#CD002255-bbs2-0066" title="OudijkMA , HeidaKY , MolBW , vanVlietEOG . Assessment of perinatal outcome by use of specific tocolytics in early labour. Subtitle: Nifedipine versus Atosiban in the treatment of threatened preterm labour. http://www.studies‐obsgyn.nl/apostel3/page.asp?page_id=931(accessed 18 November 2013). ">APOSTEL III 2011</a>; <a href="./references#CD002255-bbs2-0067" title="Gonzalez GonzalezL . Administration of Nifidepine versus Atosiban in pregnant women with a threat of premature labor. ClinicalTrials.gov (accessed 21 May 2013)2011. ">Gonzalez 2011</a>) are awaited. The role of ORA for tocolysis is the focus of another Cochrane review (review update in progress: <a href="./references#CD002255-bbs2-0102" title="PapatsonisD , FlenadyV , ColeS , LileyH . Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD004452.pub2] ">Papatsonis 2005</a>). </p> <p>There is a substantial amount of evidence from potentially eligible controlled trials (nine studies) that we were unable to include in this review due to insufficient information. Six of these trials compared CCB with betamimetic agents (<a href="./references#CD002255-bbs2-0057" title="YiCS , KimDK . A comparison of tocolytic effects of ritodrine hydrochloride and nifedipine in the treatment of preterm labour. Journal of Catholic Medical College1991;44(1):231‐8. ">Chong 1991</a>; <a href="./references#CD002255-bbs2-0059" title="DubayP , SinghalD , BhagoliwalA , MishraRS . Assessment of newborns of mothers treated with nifedipine and isoxsuprine. Journal of Obstetrics and Gynecology of India1992;42(6):778‐80. ">Dubay 1992</a>; <a href="./references#CD002255-bbs2-0062" title="MathewS , Ashok . A comparative study of tocolytic effect of nifedipine and isoxsuprine hydrochloride. Acta Obstetricia et Gynecologica Scandinavica1997;76(167):90. ">Mathew 1997</a>; <a href="./references#CD002255-bbs2-0063" title="RoyUK , PanS . Use of calcium antagonist (nifedipine) in premature labour. Journal of the Indian Medical Association1993;91(1):8‐10. ">Roy 1993</a>; <a href="./references#CD002255-bbs2-0064" title="SharmaA . A randomized comparison of nifedipine and ritodrine for suppression of preterm labour [abstract]. XVI FIGO World Congress of Obstetrics &amp; Gynecology; 2000 Sept 3‐8; Washington DC, USA. 2000:Book 2; 156. ">Sharma 2000</a>; <a href="./references#CD002255-bbs2-0065" title="SofatR , GillBK , GoyalA . Comparison of nifedipine and isoxsuprine in the arrest of preterm labour. International Journal of Gynecology and Obstetrics1994;46 Suppl:59. ">Sofat 1994</a>), two compared CCB with magnesium sulphate (<a href="./references#CD002255-bbs2-0060" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD002255-bbs2-0061" title="LotfalizadehM , TeymooriM . Comparison of nifedipine and magnesium sulfate in the treatment of preterm. Iranian Journal of Obstetrics, Gynecology and Infertility2010; Vol. 13, issue 2. ">Lotfalizadeh 2010</a>) and in one trial, CCB was compared with atosiban (<a href="./references#CD002255-bbs2-0058" title="deHeusR , MulderEJ , DerksJB , VisserGH . The effects of the tocolytics atosiban and nifedipine on fetal movements, heart rate and blood flow. Journal of Maternal‐Fetal &amp; Neonatal Medicine2009;22(6):485‐90. ">de Heus 2009</a>). The review authors regard this as an important deficiency. However, in reviewing the information currently available from these trials, it does not appear that as a group, their results differ substantially or systematically from the trials included in this review. </p> <p>Research into treatments to prevent preterm birth are challenged by the underlying mechanisms that lead to preterm labour. Preterm birth is the common final outcome of a number of interrelated pathophysiological pathways. These include intrauterine infection and inflammation, uterine overdistension (in multiple pregnancy or polyhydramnios), fetal stress responses and utero‐placental insufficiency. Tocolytic therapies largely act on the final common means which lead to labour and birth. To have a greater impact on clinical infant/child outcomes, treatments may need to address the higher order causes of preterm birth and act before the cascade of changes is set in motion. This remains a focus of ongoing scientific and clinical research. </p> </section> <section id="CD002255-sec-0109"> <h3 class="title" id="CD002255-sec-0109">Quality of the evidence</h3> <p>As blinding of intervention and outcome assessment was undertaken in only one of the included trials (a placebo controlled trial), the overall quality of the included trials is considered fair only. However, we defined objectively measured outcomes as those according to timing of birth and perinatal mortality and considered these measures to be at low risk of detection bias. One trial (<a href="./references#CD002255-bbs2-0019" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. [DOI: 10.3109/14767058.2013.847416] ">Klauser 2012</a>) used blinded assessment of all outcome measures and was considered to have low risk of detection bias for both objective and subjective outcome measures. All other trials were considered to be at high risk of detection bias for subjective outcome measures (i.e. maternal and neonatal morbidity measures). </p> <p>Sample attrition was not considered a serious source of bias as the majority had minimal or no attrition. To enable analysis by intention‐to‐treat, additional information was sought from the investigators of 13 included studies and data were provided and included for 11 of these studies. </p> <p>Selective reporting was considered possible in one trial (<a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a>) where the outcomes of pregnancy prolongation for 48 hours and until 36 weeks were omitted from the results. In 23 trials, we found no obvious evidence of reporting bias and judged these trials to be at low risk of bias. In the remaining trials it was unclear whether selective reporting bias was present. </p> <p>Sixteen studies were assessed as being at low risk of bias for other potential sources of bias based on baseline characteristics being similar between groups and no other bias apparent. In the remaining 22 studies, the risk of other sources of bias was unclear<b>.</b> One study <a href="./references#CD002255-bbs2-0009" title="GanlaK , ShroffS , DesailS , BhindeA . A prospective comparison of nifedipine and isoxsuprine for tocolysis. Bombay Hospital Journal1999;41(2):259‐63. ">Ganla 1999</a> also concluded that perinatal mortality was reduced by nifedipine, although this outcome was not reported in the results. This research article is housed on a website sponsored by a global pharmaceutical company. </p> </section> <section id="CD002255-sec-0110"> <h3 class="title" id="CD002255-sec-0110">Potential biases in the review process</h3> <p>We are aware that the review process itself is subject to bias, and we took steps to minimise bias. At least two review authors carried out data extraction and assessed risk of bias independently; however, a different review team may not have made identical decisions. </p> </section> <section id="CD002255-sec-0111"> <h3 class="title" id="CD002255-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>A series of Cochrane reviews assessed the effects of different classes of tocolytics compared with placebo, and with each other (<a href="./references#CD002255-bbs2-0074" title="BainE , HeatleyE , HsuK , CrowtherCA . Relaxin for preventing preterm birth. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010073.pub2] ">Bain 2013</a>; <a href="./references#CD002255-bbs2-0076" title="CrowtherCA , HillerJE , DoyleLW . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD001060] ">Crowther 2002</a>; <a href="./references#CD002255-bbs2-0078" title="DuckittK , ThorntonS . Nitric oxide donors for the treatment of preterm labour. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD002860] ">Duckitt 2002</a>; <a href="./references#CD002255-bbs2-0091" title="KingJF , FlenadyV , ColeS , ThorntonS . Cyclo‐oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database of Systematic Reviews2005, Issue Issue 2. [DOI: 10.1002/14651858.CD001992.pub2] ">King 2005</a>; <a href="./references#CD002255-bbs2-0102" title="PapatsonisD , FlenadyV , ColeS , LileyH . Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD004452.pub2] ">Papatsonis 2005</a>; <a href="./references#CD002255-bbs2-0112" title="SuLL , SamuelM , ChongYS . Progestational agents for treating threatened or established preterm labour. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006770.pub2] ">Su 2010</a>; <a href="./references#CD002255-bbs2-0097" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>). A review on combinations of different tocolytics for women in preterm labour is currently in development (<a href="./references#CD002255-bbs2-0095" title="NardinJM , CarroliG , AlfirevicZ . Combination of tocolytic agents for inhibiting preterm labour. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD006169] ">Nadin 2006</a>). </p> <p>A recent review of tocolytic trials, which included both network and pair‐wise meta‐analysis, examined a range of tocolytics (betamimetics, magnesium sulphate, CCB, COX inhibitors, ORA, nitric oxide donors and other drugs) (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004352.pub3/full#CD004352-bbs2-0104" target="_blank">Haas 2012</a>). The results of this review suggest that all types of tocolytics were better than placebo in terms of prolonging pregnancy beyond 48 hours, but that betamimetics performed less well than other types of tocolytics. CCB and COX inhibitors were reported to have the highest probability of delaying delivery and improving neonatal and maternal outcomes. </p> <p>The evidence regarding side effects from this review (<a href="./references#CD002255-bbs2-0085" title="HaasDM , CaldwellDM , KirkpatrickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012</a>) suggested that COX inhibitors and ORA were associated with fewer maternal side effects compared with other types of tocolytics. Our review showed a higher adverse effects profile for betamimetics and that tocolysis with CCB was associated with clinically important fewer events. A higher adverse event profile for betamimetics was shown in the Cochrane review of betamimetics compared with placebo (<a href="./references#CD002255-bbs2-0097" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>). </p> <p>Another review, using indirect comparison of randomised trials, of the CCB (nifedipine) with ORA atosiban concluded that nifedipine was more effective than atosiban and lowered the incidence of respiratory distress syndrome (<a href="./references#CD002255-bbs2-0075" title="CoomarasamyA , KnoxEM , GeeH , SongF , KhanKS . Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta‐analysis with an indirect comparison of randomised trials. BJOG: an international journal of obstetrics and gynecology2003;110:1045‐9. ">Coomarasamy 2003</a>). While, we did not show clear evidence for benefit for CCB over ORA, one small trial (145) women (which did not employ blinding of the intervention) showed some benefit in terms of preterm birth and admission to neonatal intensive care unit. Our findings are consistent with the Cochrane review on ORA for inhibiting preterm labour, which also found no clear benefit for ORA over CCB (review update in progress <a href="./references#CD002255-bbs2-0102" title="PapatsonisD , FlenadyV , ColeS , LileyH . Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD004452.pub2] ">Papatsonis 2005</a>) although ORA has advantages over CCB and other tocolytics of less maternal adverse effects. </p> <p>The CCB, nifedipine has the advantage of ease of oral administration and is very inexpensive compared with atosiban (<a href="./references#CD002255-bbs2-0101" title="PapatsonisDNM , DeckerGA . Nifedipine in the management of preterm labour: evidence from the literature. In: CritchleyH , BennettP , ThorntonS editor(s). Preterm Birth. London: RCOG Press, 2004:296‐307. ">Papatsonis 2004</a>). However, more robust evidence from well‐designed, randomised trials with direct comparisons of nifedipine and ORA are required before strong recommendations for clinical practice can be made. Consistent with our conclusions, Hass et al (<a href="./references#CD002255-bbs2-0085" title="HaasDM , CaldwellDM , KirkpatrickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012</a>) also supported further well designed, randomised, placebo controlled trials to evaluate CCB versus ORA in prolonging pregnancy for women in preterm labour. Two such studies are ongoing (<a href="./references#CD002255-bbs2-0066" title="OudijkMA , HeidaKY , MolBW , vanVlietEOG . Assessment of perinatal outcome by use of specific tocolytics in early labour. Subtitle: Nifedipine versus Atosiban in the treatment of threatened preterm labour. http://www.studies‐obsgyn.nl/apostel3/page.asp?page_id=931(accessed 18 November 2013). ">APOSTEL III 2011</a>; <a href="./references#CD002255-bbs2-0067" title="Gonzalez GonzalezL . Administration of Nifidepine versus Atosiban in pregnant women with a threat of premature labor. ClinicalTrials.gov (accessed 21 May 2013)2011. ">Gonzalez 2011</a>). Adequate comparison of CCBs with COX inhibitors (such as indomethacin) for preterm labour is also lacking. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002255-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002255-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002255-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), outcome: 2.1 Birth less than 48 hours after trial entry." data-id="CD002255-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), outcome: 2.1 Birth less than 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by agent), outcome: 2.3 Perinatal mortality." data-id="CD002255-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by agent), outcome: 2.3 Perinatal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), outcome: 2.9 Preterm birth (before completion of 37 weeks of gestation)." data-id="CD002255-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), outcome: 2.9 Preterm birth (before completion of 37 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/full#CD002255-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers compared with placebo or no treatment, Outcome 1 Birth within 48 hours after trial entry." data-id="CD002255-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers compared with placebo or no treatment, Outcome 1 Birth within 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers compared with placebo or no treatment, Outcome 2 Preterm birth (before completion of 37 weeks of gestation)." data-id="CD002255-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers compared with placebo or no treatment, Outcome 2 Preterm birth (before completion of 37 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers compared with placebo or no treatment, Outcome 3 Maternal adverse effects." data-id="CD002255-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers compared with placebo or no treatment, Outcome 3 Maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 1 Birth less than 48 hours after trial entry." data-id="CD002255-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 1 Birth less than 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 2 Very preterm birth (before completion of 34 weeks of gestation)." data-id="CD002255-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 2 Very preterm birth (before completion of 34 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 3 Perinatal mortality (stillbirth and neonatal death up to 28 days)." data-id="CD002255-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 3 Perinatal mortality (stillbirth and neonatal death up to 28 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 4 Stillbirth." data-id="CD002255-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 4 Stillbirth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 5 Neonatal death." data-id="CD002255-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 5 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 6 Maternal death." data-id="CD002255-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 6 Maternal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 7 Interval between trial entry and birth (days)." data-id="CD002255-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 7 Interval between trial entry and birth (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 8 Gestational age at birth (completed weeks)." data-id="CD002255-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 8 Gestational age at birth (completed weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-09.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 9 Preterm birth (before completion of 37 weeks of gestation)." data-id="CD002255-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 9 Preterm birth (before completion of 37 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 10 Extremely preterm birth (before completion of 28 weeks of gestation)." data-id="CD002255-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 10 Extremely preterm birth (before completion of 28 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 11 Apgar score &lt; 7 at 5 minutes." data-id="CD002255-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 11 Apgar score &lt; 7 at 5 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 12 Admission to NICU." data-id="CD002255-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 12 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 13 Respiratory distress syndrome." data-id="CD002255-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 13 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 14 Chronic lung disease." data-id="CD002255-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 14 Chronic lung disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 15 Necrotising enterocolitis." data-id="CD002255-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 15 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 16 Neonatal sepsis." data-id="CD002255-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 16 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 17 Neonatal jaundice." data-id="CD002255-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 17 Neonatal jaundice. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 18 Intraventricular haemorrhage." data-id="CD002255-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 18 Intraventricular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 19 Intraventricular haemorrhage grades 3 or 4." data-id="CD002255-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 19 Intraventricular haemorrhage grades 3 or 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 20 Periventricular leukomalacia (PVL)." data-id="CD002255-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 20 Periventricular leukomalacia (PVL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 21 Retinopathy of prematurity." data-id="CD002255-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 21 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 22 Maternal adverse effects." data-id="CD002255-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 22 Maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 23 Discontinuation of therapy for maternal adverse effects." data-id="CD002255-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 23 Discontinuation of therapy for maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 24 Caesarean section." data-id="CD002255-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 24 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 25 Duration of stay in NICU (days)." data-id="CD002255-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 25 Duration of stay in NICU (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 26 Duration of maternal hospital stay (days)." data-id="CD002255-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 26 Duration of maternal hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 27 Behavioural‐emotional problems at 9‐12 years." data-id="CD002255-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 27 Behavioural‐emotional problems at 9‐12 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 28 Special education at 9‐12 years." data-id="CD002255-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 28 Special education at 9‐12 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 29 Motor quality at 9‐12 years." data-id="CD002255-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 29 Motor quality at 9‐12 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 30 Quality of life at 9‐12 years: physical." data-id="CD002255-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 30 Quality of life at 9‐12 years: physical. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 31 Quality of life at 9‐12 years: motor." data-id="CD002255-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 31 Quality of life at 9‐12 years: motor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 32 Quality of life at 9‐12 years: autonomy." data-id="CD002255-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 32 Quality of life at 9‐12 years: autonomy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 33 Quality of life at 9‐12 years: cognitive." data-id="CD002255-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 33 Quality of life at 9‐12 years: cognitive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 34 Quality of life at 9‐12 years: social." data-id="CD002255-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 34 Quality of life at 9‐12 years: social. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 35 Quality of life at 9‐12 years: positive emotion." data-id="CD002255-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 35 Quality of life at 9‐12 years: positive emotion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 36 Quality of life at 9‐12 years: negative emotion." data-id="CD002255-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.36</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 36 Quality of life at 9‐12 years: negative emotion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-002-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-002-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 37 Parent distress scores at 9‐12 years." data-id="CD002255-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.37</div> <div class="figure-caption"> <p>Comparison 2 Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic), Outcome 37 Parent distress scores at 9‐12 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-002-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 1 Birth within 48 hours after trial entry." data-id="CD002255-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 1 Birth within 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 2 Very preterm birth (before completion of 34 weeks of gestation)." data-id="CD002255-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 2 Very preterm birth (before completion of 34 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 3 Perinatal mortality (fetal death and neonatal death up to 28 days)." data-id="CD002255-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 3 Perinatal mortality (fetal death and neonatal death up to 28 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 4 Interval between trial entry and birth (days)." data-id="CD002255-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 4 Interval between trial entry and birth (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 5 Respiratory distress syndrome." data-id="CD002255-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 5 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 6 Discontinuation of therapy for maternal adverse effects." data-id="CD002255-fig-0051" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Calcium channel blockers compared with betamimetics (subgrouped by type of CCB), Outcome 6 Discontinuation of therapy for maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 1 Birth within 48 hours after trial entry." data-id="CD002255-fig-0052" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 1 Birth within 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 2 Very preterm birth (before completion of 34 weeks of gestation)." data-id="CD002255-fig-0053" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 2 Very preterm birth (before completion of 34 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 3 Perinatal mortality (fetal death and neonatal death up to 28 days)." data-id="CD002255-fig-0054" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 3 Perinatal mortality (fetal death and neonatal death up to 28 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 4 Maternal death." data-id="CD002255-fig-0055" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 4 Maternal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 5 Interval between trial entry and birth (days)." data-id="CD002255-fig-0056" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 5 Interval between trial entry and birth (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 6 Respiratory distress syndrome." data-id="CD002255-fig-0057" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 6 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 7 Discontinuation of therapy for maternal adverse effects." data-id="CD002255-fig-0058" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB), Outcome 7 Discontinuation of therapy for maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 1 Birth within 48 hours after trial entry." data-id="CD002255-fig-0059" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 1 Birth within 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 2 Very preterm birth (before completion of 34 weeks of gestation)." data-id="CD002255-fig-0060" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 2 Very preterm birth (before completion of 34 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 3 Extremely preterm birth (before completion of 28 weeks of gestation)." data-id="CD002255-fig-0061" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 3 Extremely preterm birth (before completion of 28 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 4 Perinatal mortality (stillbirth and neonatal death up to 28 days)." data-id="CD002255-fig-0062" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 4 Perinatal mortality (stillbirth and neonatal death up to 28 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 5 Stillbirth." data-id="CD002255-fig-0063" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 5 Stillbirth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 6 Neonatal death." data-id="CD002255-fig-0064" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 6 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 7 Maternal death." data-id="CD002255-fig-0065" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 7 Maternal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 8 Interval between trial entry and birth (days)." data-id="CD002255-fig-0066" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 8 Interval between trial entry and birth (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 9 Gestational age at birth (completed weeks)." data-id="CD002255-fig-0067" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 9 Gestational age at birth (completed weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 10 Preterm birth (before completion of 37 weeks of gestation)." data-id="CD002255-fig-0068" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 10 Preterm birth (before completion of 37 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 11 Apgar score &lt; 7 at 5 minutes." data-id="CD002255-fig-0069" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 11 Apgar score &lt; 7 at 5 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 12 Admission to NICU." data-id="CD002255-fig-0070" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 12 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 13 Respiratory distress syndrome." data-id="CD002255-fig-0071" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 13 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 14 Necrotising enterocolitis." data-id="CD002255-fig-0072" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 14 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 15 Neonatal sepsis." data-id="CD002255-fig-0073" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 15 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 16 Neonatal jaundice." data-id="CD002255-fig-0074" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 16 Neonatal jaundice. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 17 Intraventricular haemorrhage." data-id="CD002255-fig-0075" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 17 Intraventricular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 18 Maternal adverse effects." data-id="CD002255-fig-0076" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 18 Maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 19 Discontinuation of therapy for maternal adverse effects." data-id="CD002255-fig-0077" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 19 Discontinuation of therapy for maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 20 Duration of stay in NICU (days)." data-id="CD002255-fig-0078" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 20 Duration of stay in NICU (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002255-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/urn:x-wiley:14651858:media:CD002255:CD002255-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_t/tCD002255-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 21 Duration of maternal hospital stay (days)." data-id="CD002255-fig-0079" src="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 Higher dose calcium channel blockers compared with lower dose calcium channel blockers, Outcome 21 Duration of maternal hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/media/CDSR/CD002255/image_n/nCD002255-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD002255-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Calcium channel blockers compared with placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth within 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.21, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth (before completion of 37 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>49.89 [3.13, 795.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Calcium channel blockers compared with placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002255-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth less than 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 CCB versus glyceryl trinitrate (GTN) patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.22, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.37, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.29, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.61, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Very preterm birth (before completion of 34 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.66, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.31, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.86, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Perinatal mortality (stillbirth and neonatal death up to 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.53, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.52, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.36, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.10, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.15, 7.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.10, 57.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.53, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.30, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.10, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Interval between trial entry and birth (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.38 [0.25, 8.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.63 [‐8.80, 5.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [‐0.96, 12.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Gestational age at birth (completed weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.34, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.22, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.25, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.51, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Preterm birth (before completion of 37 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.80, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.47, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Extremely preterm birth (before completion of 28 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.04, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Apgar score &lt; 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.26, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.48, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.17, 20.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.63, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.48, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.41, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.48, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.28, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Chronic lung disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.05, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.13, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.14, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.47, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.31, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.24, 8.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.25, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Neonatal jaundice <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Intraventricular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.34, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.30, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.09, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.23, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Intraventricular haemorrhage grades 3 or 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.23, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Periventricular leukomalacia (PVL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.02, 6.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.04, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.24, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.40, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.61 [1.43, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.81, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5 CCB versus glyceryl trinitrate (GTN) patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.23, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Discontinuation of therapy for maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.10, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.10, 25.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [0.12, 67.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.22, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.38, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.21, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Duration of stay in NICU (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 CCB versus magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.55 [‐8.17, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 CCB versus oxytocin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.4 [‐10.84, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 CCB versus non‐steroidal anti‐inflammatory drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [‐8.27, 15.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Duration of maternal hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐1.04, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Behavioural‐emotional problems at 9‐12 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐6.42, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Special education at 9‐12 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.19, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Motor quality at 9‐12 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.30 [‐9.96, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Quality of life at 9‐12 years: physical <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐3.00, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 Motor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.15, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.3 Autonomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.57, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.4 Cognitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.58, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.5 Social</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.99, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.6 Positive emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.7 Negative emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Quality of life at 9‐12 years: motor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.15, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 Autonomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.57, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.3 Cognitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.58, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.4 Social</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.99, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.5 Positive emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.6 Negative emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Quality of life at 9‐12 years: autonomy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.57, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 Cognitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.58, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3 Social</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.99, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.4 Positive emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.5 Negative emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Quality of life at 9‐12 years: cognitive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.58, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Social</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.99, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Positive emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.4 Negative emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Quality of life at 9‐12 years: social <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.99, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 Positive emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.3 Negative emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Quality of life at 9‐12 years: positive emotion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 Negative emotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Quality of life at 9‐12 years: negative emotion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Parent distress scores at 9‐12 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 CCB versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐9.25, 7.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Calcium channel blockers compared with any other tocolytic agent (subgrouped by other tocolytic)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002255-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Calcium channel blockers compared with betamimetics (subgrouped by type of CCB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth within 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Nifedipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Nicardipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Very preterm birth (before completion of 34 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nifedipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.66, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Nicardipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Perinatal mortality (fetal death and neonatal death up to 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nifedipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.53, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Nicardipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 6.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Interval between trial entry and birth (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nifedipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.38 [0.25, 8.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Nicardipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nifedipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.48, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Nicardipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuation of therapy for maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nifedipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.11, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Nicardipine compared with betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Calcium channel blockers compared with betamimetics (subgrouped by type of CCB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002255-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth within 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Nifedipine compared with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.60, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Nicardipine compared with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.30, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Very preterm birth (before completion of 34 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nifedipine compared with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.78, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Nicardipine compared with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.25, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Perinatal mortality (fetal death and neonatal death up to 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nifedipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.36, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Nicardipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nifedipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Nicardipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Interval between trial entry and birth (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nifedipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.80 [‐18.59, 6.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Nicardipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐8.37, 8.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nifedipine compared with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.56, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Nicardipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.23, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Discontinuation of therapy for maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Nifedipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.01, 101.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Nicardipine compared with with magnesium sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.41 [0.14, 82.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Calcium channel blockers compared with magnesium sulphate (subgrouped by type of CCB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002255-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Higher dose calcium channel blockers compared with lower dose calcium channel blockers</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth within 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.26, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Very preterm birth (before completion of 34 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.31, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Extremely preterm birth (before completion of 28 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.05, 5.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Perinatal mortality (stillbirth and neonatal death up to 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Interval between trial entry and birth (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.30 [‐2.21, 16.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Gestational age at birth (completed weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.03, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Preterm birth (before completion of 37 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.63, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Apgar score &lt; 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.31, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.26, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.01, 4.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.23, 5.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Neonatal jaundice <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.31, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Intraventricular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.33, 3.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Discontinuation of therapy for maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.4 [0.27, 109.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Duration of stay in NICU (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.80 [‐8.73, ‐0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Duration of maternal hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐1.59, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Higher dose calcium channel blockers compared with lower dose calcium channel blockers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002255.pub2/references#CD002255-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002255.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002255-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002255-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002255-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD002255-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD002255-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD002255-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002255\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002255\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002255\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002255\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002255\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002255.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002255.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002255.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002255.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002255.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714451044"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002255.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714451047"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002255.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6efddca49377',t:'MTc0MDcxNDQ1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 